Novel travel time aware metapopulation models and multi-layer waning immunity for late-phase epidemic and endemic scenarios

Henrik Zunker[1], René Schmieding[3], David Kerkmann[3], Alain Schengen[2], Sophie Diexer[4], Rafael Mikolajczyk[4], Michael Meyer-Hermann[3], Martin J. Kühn[1,5]

1 Institute of Software Technology, Department of High-Performance Computing, German Aerospace Center, Cologne, Germany, **2** Institute for Transport Research, German Aerospace Center, Cologne, Germany **3** Helmholtz Centre for Infection Research, Brunswick, Germany **4** Institute for Medical Epidemiology, Biometrics and Informatics, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle, Germany **5** Life and Medical Sciences Institute, University of Bonn, Bonn, Germany

Abstract

In the realm of infectious disease control, accurate modeling of the transmission dynamics is pivotal. As human mobility and commuting patterns are key components of communicable disease spread, we introduce a novel travel time aware metapopulation model. Our model aims to enhance estimations of disease transmission. By providing more reliable assessments on the efficacy of interventions, curtailing personal rights or human mobility behavior through interventions can be minimized. The proposed model is an advancement over traditional compartmental models, integrating explicit transmission on travel and commute, a factor available in agent-based models but often neglected with metapopulation models.

Our approach employs a multi-edge graph ODE-based (Graph-ODE) model, which represents the intricate interplay between mobility and disease spread. This granular modeling is particularly important when assessing the dynamics in densely connected urban areas or when heterogeneous structures across entire countries have to be assessed. The given approach can be coupled with any kind of ODE-based model.

In addition, we propose a novel multi-layer waning immunity model that integrates waning of different paces for protection against mild and severe courses of the disease. As this is of particular interest for late-phase epidemic or endemic scenarios, we consider the late-phase of SARS-CoV-2 in Germany.

The results of this work show that accounting for resolved mobility significantly influences the pattern of outbreaks. The improved model provides a refined tool for predicting outbreak trajectories and evaluating intervention strategies in relation to mobility by allowing us to assess the transmission that result on traveling. The insights derived from this model can serve as a basis for decisions on the implementation or suspension of interventions, such as mandatory masks on public transportation. Eventually, our model contributes to maintaining mobility as a social good while reducing exuberant disease dynamics potentially driven by travel activities.

Author summary

As human contacts and contact networks are key to the development and prediction of infectious disease spread, travel and commuting activities are important components to

---

be considered in mathematical-epidemiological modeling. Two, often contrasting modeling approaches, based on subpopulations and based on individuals can provide insights of different granularity but also come at different levels of complexity.

With this article, we extend a recently introduced Graph-ODE-based model by the explicit introduction of mobility-based infection models in which we allow focused nonpharmaceutical interventions, like face mask mandates in public transport, and in which we can explicitly keep track of secondary cases induced by travel activities, a component mostly not available with equation-based models. In addition, we introduce a novel multi-layer waning immunity model particularly suitable for late-phase epidemic or endemic scenarios.

On a daily level and geographically small scale, the newly proposed model often develops similarly, although our results show that complex mobility networks can lead to substantially different disease dynamics in the entirety of a federal state or country. The proposed model thus enables a better understanding of infectious disease dynamics through mobility. It allows for targeted numerical investigations and thus leads to more appropriate real-world interventions.

Introduction

According to the World Health Organization (WHO), the COVID-19 pandemic resulted in 14.9 million excess deaths in 2020 and 2021. Despite ongoing efforts to tackle infectious diseases, WHO predictions foresee communicable diseases to still account for 6 % of global deaths by 2048 [1]. The unprecedented development and administration of COVID-19 vaccines has undoubtedly saved many lives and years of live [2]. Past experiences have illustrated that waning immunity [2] and reduced vaccine protection against simple transmission (i.e., any infection) may require continuous pairing of vaccination with nonpharmaceutical interventions (NPIs) such as face masks or physical distancing, in particular in situations of high transmission [3]. For instance, after several vaccination campaigns, most SARS-CoV-2 related interventions had been discontinued in Germany until summer or early autumn 2022. To further protect vulnerable groups, FFP2 masks became mandatory in all long-distance trains on October 1st, 2022 and federal states could implement additional mask mandates in local or regional public transport [4].

In order to proactively react to infectious disease propagation, mathematical models are of great aid. Models of different types have been largely used to guide policy-makers towards evidence-based decisions, see, e.g [5] for autumn and winter scenarios in Germany in 2022/2023. To increase their impact, models should be combined with automated pipelines [6] and user-centric visual analytics tools [7] to allow for swift and optimized reaction. Over the last years, contributions have been made by a variety of different approaches, to predict SARS-CoV-2 development in Germany. Among these approaches are agent-based and individual-based models [8–11], models based on ordinary differential equations (ODE) [12–14], delay differential equations [15], integro-differential equation-based models [16], advanced ODE-based models [17] using the linear chain trick [18,19] to waive the implicit assumption of exponentially distributed transition times, hybrid agent-metapopulation models [20], and in particular standard [21–24] or graph-ODE [25] metapopulation models. From the international community, an even ampler set of models has been suggested to mitigate the spread of SARS-CoV-2. Some highly recognized international models can be found in [10, 11, 26, 27].

Mathematical models based on systems of ODEs, often denoted compartmental models, are popular tools used in the context of modeling infectious diseases, see, e.g., [28]. This is due to their well-understood character and established methods for

model analysis but also because of the low computational cost. However, transmission dynamics of communicable diseases naturally follow the complex network structures of human mobility. Standard ODE-based metapopulation (see, e.g., [21–24]) or Graph-ODE models [29] can be seen as a simple compromise between too simple ODE-based and complex agent-based models. They combine the low computational effort of ODE-based modeling on small- or medium-sized regional entities with realistic mobility networks between these regions.

Although we see certain advantages of Graph-ODE models [29] over classic ODE-based metapopulation approaches, the model in [29] neglected travel times and explicit transmission during commuting. In the current paper, we propose an extended travel time-aware Graph-ODE model that allows for explicit modeling of travel time and transmission on travel and commute.

Aside from mobility, disease dynamics can be driven or mitigated by non-protection or protection against a given pathogen. In particular for late-phase epidemic or endemic scenarios, waning immunity is an important factor to be considered. However, a recent review study [30] on models used in different forecast and scenarios hubs showed that only four out of 90 models provided information or modeling on waning immunity. We thus propose a multi-layer waning immunity model based on ordinary differential equations. In this model, we can consider three different subpopulations with corresponding immunity layers and protection factors. Furthermore, protection against mild and severe courses of the disease wane with different paces.

The current paper is organized as follows. In the first part of materials and methods, we introduce a simple ODE-SIR model and extend it by a mobility-model. We then extend a recently proposed hybrid Graph-ODE ansatz to use our novel travel-time aware model locally. Then, we additionally introduce an advanced ODE-SECIRS model containing three different immunity layers and two different paces for waning immunity, against any and severe infection, respectively. Then, we provide parameters for mobility, contact patterns, and transmission dynamics. In the results section, we show how the new model advances the previous one. Eventually, we discuss advantages and limitations and draw a conclusion.

Materials and methods

In this section, we will introduce a novel travel time aware metapopulation model which will be implemented in a multi-edge graph based on [29] to account for spatially heterogeneous disease dynamics. For a county-level resolution of Germany, we provide travel and commute patterns based on [31]. Furthermore, we introduce a multi-layer waning immunity model based on ordinary differential equations (ODEs) and which is of particular interest in late-phase epidemic or endemic scenarios. Finally, we will summarize parameters used in our estimations for the late-phase SARS-CoV-2 demonstrator case.

A novel travel time aware metapopulation model

For compartment-based modeling, we need to define a list of *disease* or *infection states*. In the simplest SIR case, we have the states *Susceptible* for persons who can get infected, *Infected* or *Infectious* for persons who can infect others, and *Recovered* or *Removed* for individuals that cannot get reinfected. In order to introduce our travel time aware

metapopulation model, we start from this simple ODE-SIR model which writes

$$S^{(k)'}(t) = -\lambda^{(k)}(t)S^{(k)}(t)$$

$$I^{(k)'}(t) = \lambda^{(k)}(t)S^{(k)}(t) - \frac{1}{T_I^{(k)}}I^{(k)}(t)$$

$$R^{(k)'}(t) = \frac{1}{T_I^{(k)}}I^{(k)}(t) \tag{1}$$

$$\lambda^{(k)}(t) = \rho^{(k)}(t)\phi^{(k)}(t)\frac{I^{(k)}(t)}{N^{(k)}(t)}$$

and where $\phi^{(k)}(t)$ represents the (mean) daily contacts of a person at time t, $\rho^{(k)}(t)$ the (mean) transmission risk, $T_I^{(k)}$ the (mean) time a person stays infected, and $N^{(k)} = N^{(k)}(t) = S^{(k)}(t) + I^{(k)}(t) + R^{(k)}(t)$ the (constant) total population size. Note that in these model, we always use mean or averaged values so that we drop the *mean* or *average* description to parameters in the following.

For the sake of a consistent development of the new model, we have already introduced the index k that will later be used to refer to a particular region k but which is without meaning for the presentation in this subsection.

We suppose some initial conditions at t_0 to be given by $(S^{(k)}(t_0), I^{(k)}(t_0), R^{(k)}(t_0))$.

In infectious disease modeling, the number of daily contacts is often estimated from surveys or contact diaries like [32]. These surveys provide us with average contact information $\phi^{(k)}$, summed for all contact locations, and, in particular, traffic-related contacts $\phi_{tr}^{(k)}$. In our model, we allow for nonpharmaceutical interventions that change the daily number of contacts over time. Consequently, we write $\phi^{(k)}(t) := \omega^{(k)}(t)\phi^{(k)}$ and $\phi_{tr}^{(k)}(t) := \omega_{tr}^{(k)}(t)\phi_{tr}^{(k)}$, where $\omega^{(k)}(t)$ and $\omega_{tr}^{(k)}(t)$ are suitable reduction factors of the registered baseline contacts.

In the following paragraphs, we will introduce our mobility-model approach for ODE-based models.

Classic traffic contacts integration and traffic-related NPIs
A straightforward approach modeling (local) traffic-related contacts in compartmental models is given with a separation of contacts in traffic and nontraffic. We can then write

$$\phi^{(k)}(t) = \phi_{tr}^{(k)}(t) + \phi_{nt}^{(k)}(t) \tag{2}$$

where $\phi_{nt}^{(k)}(t)$ represents all contacts that happen elsewhere, i.e., in home, school, workplace, or leisure activity settings. If Eq (2) is plugged into Eq (1), we can model a reduction in travel contacts from day $t_1 > t_0$ with factor $r \in [0,1]$ by using

$$\widetilde{\phi}_{tr}^{(k)}(t) := \begin{cases} \phi_{tr}^{(k)}(t), & t \leq t_1 \\ \widehat{\phi}(t), & t \in (t_1, t_1 + \delta), \quad 0 < \delta < 1, \\ (1-r)\phi_{tr}^{(k)}(t - \delta), & t \geq t_1 + \delta \end{cases} \tag{3}$$

where we define δ as a transition interval and $\widehat{\phi}$ as a transition contact rate between the change of the contact rate to ensure that $\widetilde{\phi}_{tr}^{(k)}(t) \in \mathcal{C}^1((t_1 - \epsilon, t_1 + \delta + \epsilon))$ with $0 < \epsilon \ll 1$ for Eq (1) to be well defined.

This type of contact reduction for contact locations such as *home*, *school*, *work*, and *other* has been considered in [25, 29, 33]. For noncontinuously differentiable parameters, we actually compute the solution of a new initial value problems (IVP) from t_1.

Explicit traffic or mobility modeling

Fig 1. Compartmental transmission model (white) complemented by compartmental transmission mobility model (gray).

In order to separate disease dynamics on travel and commute from nontraffic (i.e., home or work) dynamics, we propose a new way by introducing a mobility-based infection model in which dynamics follow the same mechanisms but in which the population distribution as well as transmission or mitigation parameters differ; see Fig. 1. In the following and for the sake of simplicity, we will refer to the mobility-based infection model simply as *mobility model* or *traffic model*. Note that this model basically is a pure infection dynamics model but is specifically parametrized to represent mobility settings.

Note that the novel model is indeed different and expected to behave different where it relaxes assumptions such as homogeneous mixture. However, for meaningful comparisons and in order to be consistent, contact patterns across both models have to be adjusted. In the following, we will explain how to scale contacts that are obtained from classical diary studies to our new model.

Without loss of generality, let us assume that all individuals have contacts in nontraffic locations (which is trivial, i.e., in home or work). However, only a subset $p_{tr}^{(k)} \in [0, 1]$ of individuals also have contacts in traffic locations, as some people may not commute at all or may use private transportation modes such as cars without additional passengers such that they do not come into contact with others (on commuting itself). For demonstration purposes, we consider the classic and the new model on a timescale of one day, where each day has unit length, and neglect the daily return trip for now. In the final implementation, this approach is then just down-scaled to half-a-day.

As we are still working with a mean-value model, we assume that mobility completely happens either at the beginning or the end of the day, respectively. We will provide graphs for both realizations, but provide the following description with mobility taking place at the end of the day. To that end, we introduce the daily travel time $0 \ll t_{tr}^{(k)} < 1$, such that the mobility process starts near the end of the day. Note that we will later use a time scale of half a day, with a *length of stay* in another region and *return trip* to the home region, once we introduced a second spatial region. For a visualization on the final implementation with round trips and stay times in other nodes, see Fig. 4 (right).

We further assume that the number of contacts in nontraffic locations, $\phi_{nt}^{(k)}(t)$, is independent of the additional contacts during travel, e.g., the sole fact that a person commutes or uses public transport does (on average) not reduce the number of contacts to family members, friends, or colleagues. In order to compute the number of contacts in traffic modes per individual traveler, we compute

$$\phi_{tr|tr}^{(k)}(t) := \frac{N^{(k)}\phi_{tr}^{(k)}(t)}{p_{tr}^{(k)}N^{(k)}} = \frac{\phi_{tr}^{(k)}(t)}{p_{tr}^{(k)}}. \tag{4}$$

The end-of-day approximation of our novel model is then given after solving three initial value problems. We solve

$$\text{Eq (1)} \quad \text{with} \quad \phi^{(k)}(t) := (1 - p_{tr}^{(k)})\phi_{nt}^{(k)}(t) + p_{tr}^{(k)}\frac{\phi_{nt}^{(k)}(t)}{t_{tr}^{(k)}}, \quad t \in [0, t_{tr}^{(k)}], \tag{5}$$

with initial values $(S_0, I_0, R_0) := (S^{(k)}(0), I^{(k)}(0), R^{(k)}(0))$. The scaling of contacts comes from the fact that $p_{tr}^{(k)}N^{(k)}$ many individuals now have all their nontraffic related contacts within $t_{tr}^{(k)}$ many days, $t_{tr}^{(k)} < 1$. This means that the value $\phi_{nt}^{(k)}(t)$, given on daily scale, needs to be rescaled. Let $\widehat{y}(t_{tr}^{(k)}) := (\widehat{S}^{(k)}(t_{tr}^{(k)}), \widehat{I}^{(k)}(t_{tr}^{(k)}), \widehat{R}^{(k)}(t_{tr}^{(k)}))$ be the solution of (5) at $t_{tr}^{(k)}$. We define the IVP

$$\text{Eq (1)} \quad \text{with} \quad \phi^{(k)}(t) := \phi_{nt}^{(k)}(t), \quad t \in [t_{tr}^{(k)}, 1], \tag{6}$$

with initial values $(1 - p_{tr}^{(k)})\widehat{y}(t_{tr}^{(k)})$ and a total population of $(1 - p_{tr}^{(k)})N^{(k)}$, i.e., the people that do not travel, in the denominator. Furthermore, we define the IVP in the travel node by

$$\text{Eq (1)} \quad \text{with} \quad \phi^{(k)}(t) := \frac{\phi_{tr|tr}^{(k)}(t)}{1 - t_{tr}^{(k)}}, \quad t \in [t_{tr}^{(k)}, 1], \tag{7}$$

with initial values $p_{tr}^{(k)}\widehat{y}(t_{tr}^{(k)})$ and a total population of $p_{tr}^{(k)}N^{(k)}$ in the denominator. The complete solution at $t = 1$ is then given by the summed solutions of (6) and (7). Geometrically, IVPs (5) and (6) are assigned to the white local model from Fig. 1, while (7) corresponds to the grey traffic or mobility model.

Here, with $p_{tr}^{(k)}$ and $1 - p_{tr}^{(k)}$, we used an equal and potentially unrealistic distribution of the population compartments to traffic and nontraffic node, respectively. In a more complex model, one would also reduce the relative share of infected commuters, letting $p_{tr}^{(k)}$ susceptible but only $\zeta p_{tr}^{(k)}$, $\zeta \in [0, 1)$, infected individuals commute. This reduction has already been used in [29] and naturally translates to our new model.

In Fig. 2, we provide two examples of our new model for the parameters $\phi_{nt}^{(k)} = 9$, $\phi_{tr}^{(k)} = 1$, $p_{tr}^{(k)} = 0.1$, $T_I^{(k)} = 8$, $I_0^{(k)} = R_0^{(k)} = 2$, $N_0^{(k)} = 10000$, $t_{tr}^{(k)} = 0.9$ and $\rho(t) = 0.05$ (left) and $\rho(t) = 0.1$ (right). In the new model, even if the total number of contacts stays the same, the contact structure changes from an average of ϕ to a bimodal contact distribution. We see that, both, the mobility-first and mobility-last approach end up with roughly the same number of infections at the end of the day but with, of course, slightly different numbers of susceptible and recovered individuals. We demonstrate the application of the scaling procedure to real contact data in the section *Mobility and contact patterns*.

In the end, model (1) can be substituted with any type of (complex) ODE-based model (not yet integrating mobility processes). However, the modeling of the transmission process can be very different. In other models, a single parameter, often referred to as β, is used to represent the transmission dynamics [28, 34, 35] and [21–24] directly integrate transmission on or after commuting in the force of infection. In the given presentation, we split this parameter into two different factors, the transmission probability per contact ρ and the contact rate ϕ. This decomposition allows for a more detailed and flexible parametrization of the transmission process. On top of this splitting, we add a second model realizing transmission on commuting and travel. This additional model can be used, independent of the underlying transmission dynamics model. We admit that by this splitting, seasonal mobility effects are not yet taken into account. However, seasonality is integrated by a parametric trigonometric curve as first

described in [29]. This means that seasonality can also be interpreted as a change in the effective contact rate over time. For more details also see (16).

Theoretical properties of the novel mobility model

In order to give the motivation for our scaling, we assume constant contact patterns over the considered day, i.e., $\phi_{nt}^{(k)}(t) = \phi_{nt}^{(k)}$ and $\phi_{tr}^{(k)}(t) = \phi_{tr}^{(k)}$, $t \in [0,1]$. For the total number of contacts, we then directly obtain

$$
\int_0^{t_{tr}^{(k)}} N^{(k)} \left((1-p_{tr}^{(k)})\phi_{nt}^{(k)} + p_{tr}^{(k)} \frac{\phi_{nt}^{(k)}}{t_{tr}^{(k)}} \right) \mathrm{d}t + \int_{t_{tr}^{(k)}}^1 (1-p_{tr}^{(k)})N^{(k)}\phi_{nt}^{(k)} \mathrm{d}t
$$

$$
+ \int_{t_{tr}^{(k)}}^1 p_{tr}^{(k)} N^{(k)} \frac{\phi_{tr|tr}^{(k)}}{1-t_{tr}^{(k)}} \mathrm{d}t \tag{8}
$$

$$
= N^{(k)} \left((1-p_{tr}^{(k)})\phi_{nt}^{(k)}t_{tr}^{(k)} + p_{tr}^{(k)}\phi_{nt}^{(k)} + (1-p_{tr}^{(k)})\phi_{nt}^{(k)}(1-t_{tr}^{(k)}) + \phi_{tr}^{(k)} \right)
$$

$$
= N^{(k)} \left(\phi_{nt}^{(k)} + \phi_{tr}^{(k)} \right),
$$

where we recognize Eq (2).

Let us note that the parameters of baseline contacts in traffic $\phi_{tr}^{(k)}$ as well as the travel time $t_{tr}^{(k)}$ that implicitly appear in (7) need to fit together, e.g., coming from reliable data sources of the same country. That means that the model outcome for, e.g., fixed $\phi_{tr}^{(k)}$ and arbitrary $t_{tr}^{(k)}$ is not anymore in line with the data used in the model. However, in the following sections, we still allow a certain variance in travel time between different regions, i.e., $1 - t_{tr}^{\max} < 1 - t_{tr}^{(k)} < 1 - t_{tr}^{\min}$, $k \in \{1, \ldots, n\}$. Due to data sparsity, i.e., no individual traffic contact records for arbitrary commuting routes ($\phi_{tr}^{(k)} = \phi_{tr}$, $k \in \{1, \ldots, n\}$), we only assume that

$$
\frac{\phi_{tr}}{1-t_{tr}^{\max}} := \text{const} \tag{9}
$$

to consider the limit case without travel times, instead of directly considering (7).

Considering the limit $t_{tr}^{(k)} \to 1$ implies $\phi_{tr}^{(k)} \to 0$ (with the same convergence rate). From (2), we have

$$
\phi^{(k)}(t) \to \phi_{nt}^{(k)}(t) \tag{10}
$$

and (5) also reduces to (10) on $t \in [0,1]$. The corresponding IVPs (6) and (7) can be dropped as the interval converges to a null set and the parameters remain bounded.

Thus, we see that the novel model advances the previous model [29] by removing the unrealistic assumption of instantaneous travel and allowing for realistic travel times $1 - t_{tr}^{(k)}$.

Mobility complemented metapopulation models through a multi-edge graph
In order to make use of the novel model from the previous section, assume n different geographic units (here, denote *regions*) to be given. We now combine our novel mobility model extension of a simple ODE model with the graph approach proposed in [29]. For the paper to be self-contained, we visualize the previous approach in Fig. 3 (left). There, each region is represented by the node of a graph while the (multi-)edge $\mathcal{E}_{ij}$ between nodes $\mathcal{N}_i$ and $\mathcal{N}_j$ represents the (outgoing) mobility and mobility-based exchange is realized instantly twice a day (round trip). In practice, each combination of sociodemographic group g_l, $l = 1, \ldots, G$ and infection state z_l, $l = 1, \ldots, Z$ can be assigned a number of travelers such that the multi-edge consists of $G \times Z$ single edges. Return trips are realized by a mapping on the same edge, as the vector of weights on $\mathcal{E}_{ij}$

Fig 2. Infection curves for simple (blue) and mobility-based infection model (orange and green) approach. The orange curve shows the dynamics with mobility first while the green curve shows the mobility last approach. The example's parameters are $\phi_{nt}^{(k)} = 9$, $\phi_{tr}^{(k)} = 1$, $p_{tr}^{(k)} = 0.1$, $T_I = 8$, $I_0^{(k)} = R_0^{(k)} = 2$, $N_0^{(k)} = 10000$, $t_{tr}^{(k)} = 0.9$ and $\rho(t) = 0.05$ (left) and $\rho(t) = 0.1$ (right). In the legend of the plots, we abbreviate nontraffic with NT and traffic with T.

represents the number of outgoing travelers. For the sake of a simple visualization in Fig. 3 (left), each region was assigned an ODE-SIS model with only two compartments (S and I) and two (sociodemographic) groups (e.g., age groups).

Fig 3. Hybrid graph-ODE approach [29] (left) and novel extension with mobility models (right). For simplification, we visualized an SIS model with two sociodemographic groups (e.g. age groups). In the old approach (left), no travel time was used while the novel approach models (right) travel time through compartmental mobility models.

This approach extends classic ODE-based models but simplifies the mobility pattern by instantaneously transferring commuters to their intended destinations, omitting the duration of transit. Upon reaching their destinations, individuals remain there for the day's remainder before they immediately return to their origin. In Fig. 4 (left), we provide a schematic representation of the mobility distribution under this mobility scheme. This assumption offers the advantage of facilitating the coordination and incorporation of commuters into and out of various regions by standardizing the timing of exchanges. It affords flexibility in selecting larger time steps for the applied numerical integration scheme. However, it also abstracts away critical variables such as the travel time. The instantaneous nature of exchanges precludes the possibility of transmission events during transit, an aspect that can become significant in disease spread modeling.

Deviating from this approach, our novel approach introduces a refined segmentation of the mobility activity schedule by delineating distinct mobility profiles based on local

travel and stay times; see Fig. 4 (right). The length of stay can be chosen differently for each region. An even more refined selection, e.g., an individual selection for each edge (i.e., a subpopulation of a predefined socioecomic group with a given infection state), would make the scaling of the contacts considerably more complex. This granular approach not only enhances the precision of our method but also mirrors the complex, real-world patterns of human movement more closely. However, including these details means that mobility activities are much more spread out throughout the daily schedule. Therefore, we have to choose substantially smaller time steps in the numerical integration scheme in order to take into account outgoing or incoming commuters.

Fig 4. Timing of the mobility activities. The hybrid Graph-ODE approach from [29] (left) synchronizes population exchanges at two common daily junctures. The new approach (right) defines an individual structure of mobility activities for each commuter group, which is considering the travel time and the length of stay in the destination. Within this daily schedule, all commuters still return to their home location at the same time, exactly at the end of the day.

In the novel approach, traveling is realized via mobility or traffic models; see Fig. 3 (right). Again, each region gets assigned a local compartmental model, now complemented by a local compartment mobility model.

A key advantage of augmenting the framework with local compartment mobility models lies in the creation of realistic travel chains. The idea is that commuters pass through other regions during the trip and that the individuals spend time in the mobility models of the region they are passing through. This temporary inclusion enables potential interactions with other commuter groups that are simultaneously represented in the same mobility model.

The trip chain $\mathcal{T}^{(j,k)}$ between two arbitrary nodes $\mathcal{N}_j$ and $\mathcal{N}_k$ is defined as an ordered tuple of regions,

$$\mathcal{T}^{(j,k)} = (\mathcal{N}_j, \mathcal{N}_{R_1}, \mathcal{N}_{R_2}, ..., \mathcal{N}_k), \quad R_i \in \{1, \ldots, n\} \setminus \{j, k\}, \tag{11}$$

where j is the index of the starting node, k is the index of the destination node. The transit nodes $\mathcal{N}_{R_1}, \mathcal{N}_{R_2}, \ldots$ describing the way of travel between these regions.

The construction of these travel chains is achieved by calculating the centroids of both the origin and destination regions, represented by (multi-)polygons. A line is then drawn between these centroids; see Fig. 5. The sequence in which these regions are encountered along the line is crucial, as it establishes the order of the travel itinerary. In the final step, the overall travel duration is allocated proportionally across the regions in the defined trip chain.

Fig 5. Determination of the path chains. Given several regions, we draw a line between the start and destination region (left). Afterwards we consider all regions that are hit by this line and determine the path chain based on the order (right). Using geodata "Verwaltungsgebiete 1:2 500 000, Stand 01.01. (VG2500)" from https://gdz.bkg.bund.de, copyright; GeoBasis-DE / BKG 2021, license dl-de/by-2–0, see https://www.govdata. de/dl-de/by-2-0.

Given that the visualized trip from Region $\mathcal{N}_i$ to Region $\mathcal{N}_k$ in Fig. 3 (right) is a direct trip, a traveler spends half of the travel time in each of the corresponding two mobility models. For a trip from Region $\mathcal{N}_i$ to Region $\mathcal{N}_j$, dissected to a trip chain $\mathcal{T}^{(i,j)} = (\mathcal{N}_i, \mathcal{N}_k, \mathcal{N}_j)$, a third of the trip is spent in the single mobility models. This forms our extended hybrid graph-ODE model. The arrows in Fig. 3 (right) are representing mobility between the different mobility models.

To accurately model mobility, it is crucial to first identify which individuals are participating in commuting activities. We would like to note here that different travel restrictions can be active for each region, but there should also be the possibility of restrictions on individual edges, e.g., for the subpopulations of detected or symptomatic individuals. We determine the number of commuters in compartment $z \in \mathcal{Z}$ leaving region $\mathcal{N}_j$ for region $\mathcal{N}_k$ by

$$z^{(j,k)}(t) = \frac{z^{(j)}(t)}{N^{(j)}(t)} d_z^{(j,k)}(t)\omega_z^{(j)}C^{(j,k)}, \ z \in \mathcal{Z}, \tag{12}$$

where $\mathcal{Z}$ represents the compound of all compartments of the considered local model. Furthermore, $d^{(j,k)}$ denotes a local reduction factor in daily commuting activity which can be defined for each edge, i.e., any combination of sociodemographic group and infection state. Region-based restrictions, e.g., isolation of particular infection states or general stay home restrictions, can be chosen with $\omega_z^{(j)}$. For example, we can use $\omega_{I_{Sy,*}}^{(j)}$ to isolate symptomatic individuals and to restrict their commuting activities. Finally, we have the total number of people moving between nodes $\mathcal{N}_j$ and $\mathcal{N}_k$, denoted by $C^{(j,k)}$. In summary, we break the total given number of people moving from one region to another, into subpopulations of different infection states for which different restrictions can be applied. These numbers are time dependent.

An important challenge of the approach is tracing the compartmental affiliation of the traveling individuals. We address this issue by employing and extending the method described in [29], where we perform an approximation step using a single-step integration method. With this step, we solely advance the infection states of a focus group of individuals (i.e., travelers) while considering all other persons within the same model (travelers from other destinations and local population) as contact persons only. This approach is independent of the model selected and offers some kind of subpopulation-tracing in a population-level model. As the local travel time is generally small, we also apply a single step method for traffic nodes where only one subpopulation is present. Fig. 6 demonstrates the movement patterns of individual

groups and how interactions between different groups can lead to additional infections during a trip. Please note that visualization is based on individuals while in practice only subpopulation shares are known.

Fig 6. Demonstration of the mobility across three nodes and four edges. The travel time between region i and k, $t_{tr}^{(i,k)}$, is two times the travel time from region i to j, i.e., $t_{tr}^{(i,k)} = 2t_{tr}^{(i,j)}$. For simplification, there is no exchange between nodes k and j. The images read from top left to bottom right and all subpictures visualize the developments between (and at the end of) the considered time frame, i.e., $t_0 \rightarrow t_1$ for top left. At time t_0, for all graph nodes, travelers change from their local infection model to their local traffic infection model. During the interval $[t_0, t_1]$ (top left), state changes in traffic infection models are approximated by a single step time integration method while any other (generally an adaptive high-precision scheme like Cash Karp 5(4) [36]) method can be used in the local nodes. Subpopulations that come from or go to a different location are only considered as contact populations; see [29]. This is the first part of the functionality implemented on the graph's (multi) edges. At t_1, the exchange between nodes i and j happens. By t_1 (top right), the exchange along the edge between nodes i and j has already happened and three infected plus one recovered individual have moved from travel model of node $\mathcal{N}_j$ to travel model of node $\mathcal{N}_i$ and vice versa. In $[t_1, t_2)$, the individuals present in travel node $\mathcal{N}_i$ and subject to move to k get in contact with the individuals arriving from node $\mathcal{N}_j$. After another time step until t_2, the travelers between node $\mathcal{N}_i$ and node $\mathcal{N}_k$ are exchanged. From t_2 to t_3 (bottom left), we further advance the newly exchanged travelers to finally arrive in the local models at t_3, i.e., after they have completed their predefined travel time within the mobility model. For the local models in nodes i and j, we must update the states of the arrived individuals using the introduced method, as both local residents and travelers are present, and we will integrate new individuals to the region in the next step. By $t_3 + \varepsilon, \varepsilon > 0$ (bottom right), all individuals have reached their destination regions, i.e. the travel models are empty, and local models can be advanced in parallel.

A multi-layer waning immunity model of SECIRS-type

Waning immunity is a paramount feature in epidemiological modeling if late-phase epidemic or endemic scenarios are considered and immunity of individuals is not everlasting. This, for instance, is the case for SARS-CoV-2 or influenza, where neither infection nor vaccination establishes lasting protection against (any) re-infection; see, e.g., [37].

To motivate and, later, parametrize our model, we first looked into [37], which had considered Influenza with vaccination and reinfections (with new variants) as well as an early result for SARS-CoV-2 [2]. We then also considered two recent systematic reviews with 26 studies in [38] and 65 studies from 19 different countries in [39]. According [38], protection against hospitalisation or serious illness due to previous infections was found to be 74.6% (on average) after 12 months, waned from 80-90 % after two months. In individuals with hybrid immunity, i.e., a combination of infection and vaccination, the protective effect of hybrid immunity following primary series remained high at 97.4% after 12 months and 95.3% after 6 months following the first booster vaccination – with practically no waning detected. The paper also shows that protection against reinfection after a previous SARS-CoV-2 infection decreases from roughly 70 % after two months to 24.7% within 12 months. For individuals with hybrid immunity with primary series vaccination, protection against reinfection after the first booster vaccination fell from 75-80 % to 41.8% within one year interval. Individuals with hybrid immunity due to first booster vaccination had a protection of 46.5% after 6 months. A further systematic review and meta-analysis by [39] found similar results. Protection against (any) reinfection by the Omicron BA.1 variant fell to around 36.1% after 40 weeks, with slightly faster decline against symptomatic reinfection. Protection remained higher for earlier variants but also decreased over time. Again, protection against serious illness stayed high for all variants, including Omicron BA.1, i.e., at 88.9% after 40 weeks. Earlier variants even showed protection of over 90%. These results confirm that despite the decline in protection against reinfection, protection against severe courses lasts longer and remains robust. Overall, we conclude that the immunity and decline in immunity plays a major role in the course of time and should be considered with two different paces.

In the following, we present the full SECIRS-type model with waning immunity; see Fig. 7. The motivation for the particular model is threefold and not only in waning immunity. First, as pre- or asymptomatic transmission plays an important role for SARS-CoV-2, we use a differentiation in nonsymptomatic and symptomatic transmission to separate their related contributions to the disease dynamics. Second, we use three different layers of immunity or subpopulations with different protection factors against mild and severe courses of the disease. Finally, we introduce the compartments of *temporary immunity* to realize different paces of immune waning against mild and severe infections, respectively. As motivated above, our model realizes quickly waning protection effects against transmission or any infection while it preserves longer-lasting immunity against severe or critical infections. To account for age-specific transmission and infection parameters, our model will also be stratified for age groups. Our open-source implementation in *MEmilio* [40] allows for a variable number of age groups as well as for flexible integration of other sociodemographic factors such as income.

Our model is based on the previously developed SECIR-type model in [25] which had been assessed as high-quality by a recent meta review [41]. The model allows the integration of vaccinations and different immunity layers but lacks waning immunity. However, the introduction of the *temporary immunity* states changes the meaning of recovery. Recovery always means to enter a temporary immunity compartment and then a susceptible compartment with different protection layer. Furthermore, the states enable the simulation of waning immunity with different paces to suitably model

endemic or late-phase epidemic scenarios. The basic infection process of our model follows an *susceptible* (S), *exposed* (E), *nonsymptomatic infectious* (I_{NS} or C for carrier), and, potentially, *symptomatic infectious* (I_{Sy}), *infected severe* (I_{Sev}), *infected critical* (I_{Cr}), and *Dead* (D) structure.

We refer to the first subpopulation (shown in gray in Fig. 7) as the *naive* subpopulation. Individuals of this group have either not seen vaccination or infection, did not have a substantial immune reaction to these or immunity has waned completely, with the last infection or vaccination event long ago. Individuals with *partial immunity* (shown in purple) have an average protection, while individuals with *improved immunity* (shown in blue) are best protected against the pathogen. The arrows in Fig. 7 show a permeable model where individuals can change the subpopulation during simulation.

The different states of the model and their meanings, independent of the particular immunity, are shown in Table 1. To further motivate our model development, we have sketched out the idea of different protection layers and waning immunity paces on the individual layer in Fig. 8.

Table 1. Model compartments and meanings for disease transmission modeling.

Compartment	Symbol	Description
Susceptible	S	Currently not infected, susceptible to infection.
Exposed	E	Infected but not yet infectious.
Infected, no symptoms	I_{NS}	Infected and infectious but pre- or asymptomatic.
Infected, symptoms	I_{Sy}	Symptomatic, infected and infectious.
Infected, severe	I_{Sev}	Treated in hospital, isolated.
Infected, critical	I_{Cr}	Treated in intensive care, isolated.
Dead	D	Died, removed from model.
Temporary immunity	$\mathcal{I}$	Temporarily immune after completed vaccination or infection.

Fig 8. Motivation on different immunity layers and waning immunity waning paces on the individual layer. Recent infections or vaccinations protect against transmission or any infection for a short time. Less-recent immune boosters may not adequately protect against transmission but may result in good protection against a severe course of the disease.

In order to cover age group-specific characteristics of the viral dynamics, we stratify the population by different groups $i \in \{1, \ldots, G\}$, where G is the number of age groups. For all parameters and variables, we add the subscript i to distinguish the different age groups.

In order to introduce the model equations, we define $N_i^{(k),D^\perp}$ as people from age group $i \in \{1, \ldots, G\}$ which are not in the dead compartment. Furthermore, denote by

Fig 7. SECIRS-type model with high temporary immunity upon immunization and waning immunity over time. The three different immunity layers are visualized by different colors. The waning is represented by orange arrows. Vaccinations are visualized through dashed green arrows and reduce susceptibility for transmission for a certain (short) period of time. Recovery happens from any kind of infection state to a temporary immunity state with normal black arrow. We have highlighted the disease states responsible for transmission by red boxes. For the sake of simplification, we do not visualize the age group model here.

$z_{j,i}^{(k)}$, the j-th disease state and by $z_{j+1,i}^{(k)}$ the worsened disease state, e.g., $z_{j,i}^{(k)}$: Infectious, No Symptoms, Naive (age group i) and $z_{j+1,i}^{(k)}$: Infectious, Symptoms, Naive (age group i). We order the 18 disease states $\mathcal{Z}_I$ as follows: Exposed Naive Not Infectious, ..., Dead Naive, Exposed Partial Immunity Not Infectious, ..., Dead Improved Immunity.

Let $\mu_{z_{j,i}}^{z_{j+1,i},(k)}$ be the probability of transition from disease compartment $z_{j,i}^{(k)}$ to $z_{j+1,i}^{(k)}$. For the sake of simplicity, we dropped the second superindex (k) on $z_{j,l}$, $l \in \{i, i+1\}$ here. Then, $1 - \mu_{z_{j,i}}^{z_{j+1,i},(k)}$ is the probability to recover from disease state $z_{j,i}^{(k)}$. Let further $T_{z_{j,i}}^{(k)}$ be the time in days an individual stays in a compartment $z_{j,i}^{(k)}$. For z_j referring to a disease state with partial or improved immunity, we introduce the simplified factor κ as the counterpart of the relative reduction $1 - \kappa$ between $T_{z_{j,i}^{(k)}}^{(k)}$ and

the corresponding time spent in the naive compartment, e.g., for nonsymptomatic individuals

$$T_{I_{NS,II,i}}^{(k)} = \kappa\, T_{I_{NS,N,i}}^{(k)}. \tag{13}$$

Additionally, we define reduction factors p_* for the extended protection against severe courses in the partial and improved immunity layers. The basic functioning of these parameters can be described by

$$\mu_{z_{j,M,i}}^{z_{j+1,M,i},(k)} = \frac{p_{z_{j+1,M,i}}}{p_{z_{j,M,i}}}\mu_{z_{j,N,i}}^{z_{j+1,N,i},(k)}, \tag{14}$$

where $i \in \{1,\dots,G\}$ again denotes to the age group and $z_{j,*} \in \{I_{NS,*}, I_{Sy,*}, I_{Sev,*}, I_{Cr,*}\}$ refers to the disease states. Here, we added the index $M \in \{PI, II\}$ describing the affiliation to the immunity layer. Summarized, we use reduction factors to reduce the probabilities, which we define for the naive immunity layer, to use them with two other layers. For more details about the reduction factors, we refer to [25]. Furthermore, we define $T_{W_{PI},i}^{(k)}$ and $T_{W_{II},i}^{(k)}$ as the time spent in susceptible compartment $S_{PI,i}^{(k)}$ and $S_{II,i}^{(k)}$, respectively, if no infection event occurs, i.e., these times define the denominator of the waning rates. The (local) vaccination rates of the different immunity layers $M \in \{N, PI, II\}$ are given by $v_{M,i}^{(k)}$, $i \in \{1,\dots,G\}$. Eventually, we define by $\xi_{I_{NS},i}^{(k)}$ and $\xi_{I_{Sy},i}^{(k)}$, $i \in \{1,\dots,G\}$, the share of (locally) nonisolated nonsymptomatic and symptomatic infectious individuals.

In this section, we now provide the elementary model processes in a general representation. For the full model equations, see S1 Appendix. SECIRS-type model equations and initialization. As the susceptible compartments contain the transmission processes to the exposed compartment as well as the waning immunity from the temporary immunity compartments and to the susceptible compartment of the inferior protection layer, we provide these equations first. For the three different groups of susceptibles $M \in \{N, PI, II\}$, $i \in \{1,\dots,G\}$, these write

$$\frac{dS_{M,i}^{(k)}}{dt} = -S_{M,i}^{(k)}\rho_{M,i}^{(k)}\sum_{j=1}^{n}\phi_{i,j}^{(k)}$$

$$\frac{\xi_{I_{NS},j}^{(k)}(I_{NS,N,j}^{(k)} + I_{NS,PI,j}^{(k)} + I_{NS,II,j}^{(k)}) + \xi_{I_{Sy},j}^{(k)}(I_{Sy,N,j}^{(k)} + I_{Sy,PI,j}^{(k)} + I_{Sy,II,j}^{(k)})}{N_j^{D^\perp,(k)}} \tag{15}$$

$$- v_{M,i}^{(k)}S_{M,i}^{(k)} - \underbrace{\frac{1}{T_{W_M,i}^{(k)}}S_{M,i}^{(k)}}_{=:0 \text{ for } M=N} + \underbrace{\frac{1}{T_{W_{M+1},i}^{(k)}}S_{M+1,i}^{(k)}}_{=:0 \text{ for } M=II} + \underbrace{\frac{1}{T_{\mathcal{I}_{M,i}}^{(k)}}\mathcal{I}_{M,i}^{(k)}}_{=:0 \text{ for } M=N},$$

Here, we used the simplified notation of $M+1 = PI$ if $M = N$ and $M+1 = II$ if $M = PI$ and for the sake of a shorter presentation, we skipped the dependence on t. Furthermore, $\rho_{M,i}^{(k)}$ is the transmission risk per contact which is modeled through a baseline transmission risk $\rho_{0,N,i}^{(k)}$, a potential reduction factor for better-protected individuals $p_{E,PI}$ and $p_{E,II}$ and a parametric trignometric curve

$$\rho_{M,i}^{(k)} = \rho_{0,M,i}^{(k)}\left(1 + k\sin\left(\pi\left(\frac{t}{182.5} + \frac{1}{2}\right)\right)\right), \quad M \in N, PI, II \tag{16}$$

with $\rho_{0,PI,i}^{(k)} = p_{E,PI}\,\rho_{0,N,i}^{(k)}$ and $\rho_{0,II,i}^{(k)} = p_{E,II}\,\rho_{0,N,i}^{(k)}$ and where t is the day of the year.

Furthermore, except for the exposed and dead compartments, we can either recover from a particular disease state to a temporary immunity state or move on to an

aggravated state of the disease. For any given disease state $z_j \in \mathcal{Z}_I$ excluding the different exposed states, we can generically write

$$\frac{dz_{j,i}^{(k)}(t)}{dt} = \frac{\mu_{z_{j-1,i}}^{z_{j,i},(k)}}{T_{z_{j-1,i}}^{(k)}} z_{j-1,i}^{(k)}(t) - \frac{z_{j,i}^{(k)}(t)}{T_{z_{j,i}}^{(k)}}, \quad (17)$$

where we assume that $z_{j-1,i}$ is the previous milder infection state. For future developments and in order to determine the most influential parameters with respect to different the model outcomes, we performed a sensitivity analysis using the Morris screening method [42]. This method calculates elementary effects for each parameter by systematically varying one parameter at a time while leaving other parameters unchanged. We present the elementary effects of the individual parameters with respect to new infections and number of deaths.

In short, the sensitivity analysis indicates that the transmission risk, followed by the protection factors against any or symptomatic infection, the reduction of the infectious time for protected individuals and the overall infectious times have the highest influence on the number of new infections. The high influence of the transmission risk suggests that small changes in the probability of transmission upon contact can lead to significant variations in number of daily new infections. It should also be mentioned that a change in the probability of infection due to commutativity is equivalent to a change in the contact rate and therefore the result also applies to the latter. In terms of ICU occupancy, the analysis indicates that the probabilities of transition from the symptomatic to the severe state and from the severe state to the critical state have the highest impact, shortly followed by the transmission risk. For more details, we refer to Fig. 19 in the appendix.

In the full model equations, we also provide confirmed compartments. However, there is no flow from undetected to detected compartments in the model equations. Detection within a node is modeled implicitly via $\xi_{I_{NS,i}}$ and $\xi_{I_{Sy,i}}$. The detected compartments are only used and filled via testing on traveling and commuting. For more details, see [33]. However, this mechanism is not used in the underlying study.

An explanation of all parameters for defining the model in Eq (15) - (17) is provided in Table 2. In order to solve the local models, we use an adaptive Runge-Kutta Cash Karp 5(4) integration scheme [36] to ensure a small discretization error.

Parameterization

We will showcase our novel model with a synthetic outbreak scenario and according to the developments of SARS-CoV-2 in autumn 2022 in Germany. As reported case data is divided into the six age groups: 0-4 years, 5-14 years, 15-34 years, 35-59 years, 60-79 years, and 80 years and older, we stratify our model accordingly.

Mobility and contact patterns

The dataset user for inter-county commuting in Germany is based on a macroscopic transport model and a synthetic population for Germany. The transport model called DEMO [43] (short for *DEutschlandMOdell*, i.e., German Transport Model) is aimed to forecast transport in Germany when changing external factors like political policies or technological novelties. The model consists of multiple origin/destination (OD) matrices for each transport mode containing trip counts, average travel distances and average travel times for each origin/destination relation. Origins and destinations are described as traffic analysis zones. In this case the study area (Germany) is divided in 6633 traffic analysis zones which translates to matrices of size 6633x6633. The synthetic population is generated from the micro census 2017 and is spatially allocated to the traffic analysis

zones. Additionally each synthetic person is binned into a behavioral homogeneous person group considering attributes like age and gender. In order to generate trip chains, e.g., home → work → leisure → shopping → home, daily routines including schedules, average travel distances and times are extracted from the national household survey Mobility in Germany 2017 [44]. Counts of each routine are transformed into discrete probability distributions for each person group; for a more detailed description on the process, see [45]. Further disaggregation iterates through each person where a daily routine is picked out of the according distribution. Since routines start and end at home, the start and end zone for the first respectively the last activity is known. For all activities in between, possible destination zones are selected based on travel distance from the starting zone and the trip count from the macroscopic model. The output is a list of trips between zones for each person. Finally the data is aggregated again to an origin/destination relation level with trip counts, transport mode and person group distribution. The preliminary age-group related OD matrices have been published freely in [46]. Note that in this study age group related traffic has been recomputed by (12).

For the underlying study with an aggregated mean-value model, we only allow one travel per day and thus take workplace-related commuting from the described data set. We assume that all trips are possible in the time line of one day each. For the given data, we provide the ratio of internal and inbound commuters in Fig. 9 (left) for each county in Germany, sorted in ascending order of the internal commuter ratios. In Fig. 9 (right), we present the ratio of inbound commuters to the total local population of the considered county. The figure shows, on the one hand, the influence of inbound commuters on the number of total workers and that the share compared to the total population is relevant, if not even substantial.

(a) Compared to local commuters   **(b)** Compared to local population

Fig 9. Analysis of workplace commuting mobility in Germany. Ratio of internal commuters to inbound commuters (left) and incoming commuters against the respective local population (right). The counties are sorted in ascending order.

Local contact patterns

In the previous sections, we have already explained how we model contact patterns in mobility and nonmobility settings, given survey numbers of contact ϕ_{tr} and ϕ_{nt}. The contact rate is an elementary part of the calculation of the transmission or infection rate of the persons in the susceptible compartments. As in [29], we select contact locations *Home*, *Work*, *School*, and *Other* and choose our baseline contact patterns based on [47] and [48]. To explicitly model, the contacts in transportation, we additionally subdivide the group of *Other*. This is done based on the contact surveys in [49], which numbers have been provided with [50] in an accessible format. From this data we infer the relative share of contacts in transportation (with respect to other), to apply these factors

Table 2. Parameters used to define our multi-layer waning immunity model of SECIRS-type; Eq (15) - (17).

Parameter	Description
$\phi_{i,j}$	Daily contact rate between two age groups i and j.
$\rho_{0,N}$	Baseline transmission risk for people located in the naive susceptible compartments
k	Seasonality parameter
$N_i^{D^\perp}$	People from age group i which have not died during simulation.
$\mu_{z_1}^{z_2}$	Probability of transition from compartment z_1 to z_2.
T_{z_1}	Time in days an individual stays in a compartment z_1.
$\xi_{I_{NS},i}$	Proportion of asymptomatic infectious people who are not isolated.
$\xi_{I_{Sy},i}$	Proportion of symptomatic infectious people who are not isolated.
κ	Reduction factor for time spans of asymptomatic and symptomatic infections of individuals with partial or improved immunity.
$p_{E_{PI}}$	Effectiveness of partial immunity protection against infection.
$p_{I_{Sy},PI}$	Effectiveness of partial immunity protection against symptomatic infection.
$p_{I_{Sev},PI}$	Effectiveness of partial immunity protection against hospitalization.
$p_{I_{Cr},PI}$	Effectiveness of partial immunity protection against ICU treatment.
$p_{D_{PI}}$	Effectiveness of partial immunity protection against death.
$p_{E_{II}}$	Effectiveness of improved immunity protection against infection.
$p_{I_{Sy},II}$	Effectiveness of improved immunity protection against symptomatic infection.
$p_{I_{Sev},II}$	Effectiveness of improved immunity protection against hospitalization.
$p_{I_{Cr},II}$	Effectiveness of improved immunity protection against ICU treatment.
$p_{D_{II}}$	Effectiveness of improved immunity protection against death.
$T_{W_{PI}}$	Rate of waning immunity of susceptible who are located in the partial immunity state.
$T_{W_{II}}$	Rate of waning immunity of susceptible who are located in the improved immunity state.
v_N	Vaccination rate of people with naive immunity.
v_{PI}	Vaccination rate of susceptible with partial immunity.
v_{II}	Vaccination rate of people with improved immunity.

element-wise to the contact matrix from [47]. Inter- and extrapolation of the aggregated contact data to the given age groups is done with recent demographic data for Germany; [29]. The final contact baseline is shown in Fig. 10. Local contact reduction through NPIs is modeled as in [29] – selecting a zero minimum contact pattern.

Especially for the school contact location, vacation times are important. We have thus implemented the federal state dependent vacation times by adjusting the (school) contact matrix in the corresponding periods. We admit that our model is not (yet) adapted for, e.g., computing the import risk from hot spots outside Germany and that additional models (and data) might be needed for vacation time. This however is not the main focus of our improvement and could be addressed with other established models such as [51]. On average, however, as reported in previous publications [12, 29], the parametric trigonometric curve implemented for seasonality fits very well the observed surges and declines of infections over the year.

Fig 10. Age-resolved contact matrices for Germany. The images show the average number of contacts in each of our five contact location. Values that are zero are displayed in white.

Epidemiological parameters for SARS-CoV-2 Omicron variant BA.1/2

In the last part of materials and methods, we focus on the epidemiological parameters specific to SARS-CoV-2 omicron variant BA.1/2, our demonstration case. The introduced model is a highly detailed model. We have explained the required parameters in Table 2. Depending on the available data, we provide stratified parameter ranges. Parameters have been obtained from an extensive literature research and prior findings with our previous models in [25, 29, 33]. Given the literature findings on waning immunity as mentioned in the introduction of the waning immunity model, we implement a rather quick immune waning for any transmission, over several months, and use $T_{\mathcal{I}_{PI}} = T_{\mathcal{I}_{II}} = 60$ days. To ensure a long-term protection against severe infection, we set $T_{W_{PI}} = T_{W_{II}} = 720$ days, which means that very little waning happens in a one year time period. For a summary see Table 3. The parameters for the baseline transmission probability and the risk of being admitted to ICU were manually fitted with the observed data, starting from the findings in [29]. Theoretically, the transmission probability ρ could be chosen differently for the mobility model and the local contact model to account for varying interaction qualities. However, due to the aggregated view of ODE-based models and limited data availability, we decided to use the same value across both models, thereby assuming an identical transmission probability in both models. For most parameters, we provide a range from which we uniformly take parameter samples. By making a large number of Monte Carlo runs, we obtain good estimate of the uncertainty in the output.

To determine the initial states for the individual compartments of our model, we use the German case numbers published by the Robert Koch-Institute [67]. The idea of transforming the confirmed case data to initial states for each compartment was given in [25]. We follow this approach while implementing the changed immunity layers in this approach. For more details, we refer to S1 Appendix. SECIRS-type model equations and initialization. The presented SECIRS model is highly parameterized. We therefore use a sensitivity analysis to determine the parameters that have the greatest impact on the disease dynamics.

Table 3. Model parameters for spatially resolved model and Omicron BA.1/2. If parameters are stratified by age, vertical lines separate the corresponding columns. Column *Reference* provides used references in addition to the findings in [25, 29, 33].

Param.	0-4	5-14	15-34	35-59	60-79	80+	Reference
$\rho_{0,N}$	[0.03, 0.06]	[0.075, 0.105]			[0.12, 0.15]	[0.15, 0.225]	[29] & Fitted
k	[0.1,0.3]						[12, 25, 29]
$\xi_{I_{NS}}$	sigmoidal curve from 0.5 to 1 on incidence 10 to 20						[33]
$\xi_{I_{Sy}}$	sigmoidal curve from [0.0, 0.2] to [0.4, 0.5] on incidence 10 to 150						[33]
T_E	1.66						[52], [53], [54]
T_{INS}	1.44						[52], [54]
T_{ISy}	[6.58,7.16]						[55]
T_{ISev}	[1.8,2.3]			[2.5,3.67]	[3.5,5]	[4.91,7.01]	[56]
T_{ICr}	[9.29, 10.57]		[10.842,12.86]		[11.15, 13.23]	[11.07,13.25]	[56]
$T_{\mathcal{I}_{PI}}$	60						[57], [38]
$T_{\mathcal{I}_{II}}$	60						[57], [38]
$T_{W_{PI}}$	720						[57], [38]
$T_{W_{II}}$	720						[57], [38]
$\mu_{I_{NS}}^{I_{Sy}}$	[0.60,0.80]		[0.7,8.3]			[0.85,0.9]	[58]
$\mu_{I_{Sy,N}}^{I_{Sev,N}}$	[0.006,0.009]	[0.0048,0.0072]	[0.006,0.0092]	[0.00147,0.0222]	[0.0375,0.045]	[0.07,0.0875]	[59], [27], [60]
$\mu_{I_{Sev,N}}^{I_{Cr,N}}$	[0.0104,0.0208]	[0.0104,0.0208]	[0.0104,0.0208]	[0.0208,0.0416]	[0.052,0.0728]	[0.0728,0.0936]	[29] & Fitted
$\mu_{I_{Cr,N}}^{D_N}$	[0.00,0.039]		[0.039,0.0702]		[0.117,0.195]	[0.195,0.273]	[61], [62], [63]
κ	0.5						[64]
$p_{E_{PI}}$	1.0						[38]
$p_{I_{Sy,PI}}$	[0.039, 0.254]						[65]
$p_{I_{Sev,PI}}$	[0.18, 0.48]						[66]
$p_{I_{Cr,PI}}$	see $p_{I_{Sev,PI}}$						
$p_{D_{PI}}$	see $p_{I_{Sev,PI}}$						
$p_{E_{II}}$	1.0						[38]
$p_{I_{Sy,II}}$	[0.656, 0.705]						[65]
$p_{I_{Sev,II}}$	[0.81, 0.9]						[66]
$p_{I_{Cr,II}}$	see $p_{I_{Sev,II}}$						
$p_{D_{II}}$	see $p_{I_{Sev,II}}$						

Results

In this section, we use and validate the introduced SECIRS-type model with three different immunity layers and two paces for waning immunity and the novel travel-time

aware mobility model. 463

We will consider several settings in corresponding subsections: 464

- First, we consider the separated effects of the waning immunity model, validated 465
  qualitatively over a two years time frame with wastewater data. 466

- Second, we numerically validate that the novel mobility method is indeed a 467
  generalization of [29] and convergences to the old method if maximum travel time 468
  goes to zero. 469

- Third, we provide a synthetic outbreak scenario with a infection hotspot in 470
  Cologne and show how infection numbers spread differently with the newly 471
  introduced method. 472

- Fourth, we consider the Post-Oktoberfest and beginning of winter season, where 473
  we validate our model based on reported ICU occupancy. 474

- Finally, we provide a retrospective analysis of SARS-CoV-2 transmissions in the 475
  late phase of the pandemic and also use ICU occupancy as additional validation. 476

Validation of a global waning immunity model using wastewater data 477 478

Given the complexity of our proposed model, it is important to show the advancements 479
on the particular elements separately. Therefore, we consider the results of the 480
immune-waning model separately from the impact of the mobility scheme and use a 481
single (waning immunity) model for the whole of Germany over a two years time frame 482
(2022-2024). The parameters used in this analysis differ slightly from those used in the 483
spatially resolved model (Table 3 and Table 4) since we homogeneously aggregate 484
heterogeneous immunity dynamics over the whole of Germany. We prevented from 485
tweaking parameters too much to improve the global fit, as inferred parameters would 486
necessarily be wrong on a local scale. We use wastewater data as an unbiased estimator 487
to adequately capture disease dynamics in times of changing or absent testing strategies. 488
From Fig. 11, we see that the new model qualitatively represents the three major surges 489
and declines over the two year period indicated by the wastewater samples from the 490
AMELAG [68]. On the other hand, the old model wrongly results in an eradication of 491
the virus in the population. We furthermore see that the development of reported cases 492
diverges significantly from the wastewater measurements. We see that the global model 493
does not fit well several local peaks induced by a heterogeneous spread of COVID-19 in 494
Germany, see also the local wastewater measurements in Fig. 20 and Fig. 21. Additional 495
considerations to use and validate our novel model in different scenarios will be the 496
focus of future work. 497

Table 4. Model parameters for the global SECIRS-Type model without spatial resolution. The table shows the basic transmission probability ($\rho_i^{(0)}$) and the increased protection ($p_{E_{PI}}$ and $p_{E_{II}}$) for individuals with higher immunity.

Parameter	Age Group					
	0-4	5-14	15-34	35-59	60-79	80+
$\rho_{0,N}$	$[0.06, 0.12]$	$[0.15, 0.21]$			$[0.24, 0.3]$	$[0.3, 0.4]$
$p_{E_{PI}}$	0.4					
$p_{E_{II}}$	0.4					

Fig 11. Comparison of the simulated and reported cases with wastewater measurements over a two-year period (2022-2024). New symptomatic infected individuals simulated with novel immune-waning model (blue) and existent no-waning model (orange). Obtained AMELAG wastewater data (red) and reported cases (green). The solid line represents the median of the simulation results, while the shaded area indicates the 25th to 75th percentile.

Numerical validation of novel mobility scheme

In the section "Theoretical properties of the novel mobility model", we have already shown that the novel mobility scheme reduces to the previously suggested model [29], as the travel time approaches zero. For validation, we here present the numerical convergence of the novel model to the previously proposed model. To simplify disease dynamics, we use local SIR models (1) for the five German counties Cologne, Leverkusen, Rheinisch-Bergischer Kreis, Rhein-Sieg-Kreis, and Bonn with realistic demographies and parameters as given in Fig. 2. For the initial conditions, we set 0.1% of the total populations to be infected and zero recovered individuals. We then compute the solution over 50 days using the novel mobility scheme and subsequently evaluate the difference to the solution obtained with the existing instantaneous travel mobility scheme [29] at the last date. Table 5 shows that, as travel time decreases, the difference between the two model outputs converges to zero. Additionally, we present the convergence behavior using map plots for the different values of t_{tr}^{max} in Fig. 12.

Table 5. Numerical convergence of the novel mobility scheme. The table shows the normed difference between the outcomes of the previous and the novel mobility scheme after 50 days of simulation with values of $t_{tr}^{max} \to 0$.

t_{tr}^{max}	Difference					
	Total	*Cologne*	*Leverkusen*	*Rhein.-Berg. Kreis*	*Rhein-Sieg-Kreis*	*Bonn*
$1.00e+00$	$1.10e+05$	$4.27e+04$	$1.18e+04$	$1.48e+04$	$2.46e+04$	$1.61e+04$
$1.00e-01$	$7.81e+03$	$3.12e+03$	$8.69e+02$	$6.12e+02$	$1.73e+03$	$1.48e+03$
$1.00e-02$	$7.58e+02$	$2.92e+02$	$9.18e+01$	$1.05e+02$	$1.69e+02$	$1.01e+02$
$1.00e-03$	$7.56e+01$	$2.91e+01$	$9.15e+00$	$1.04e+01$	$1.69e+01$	$1.01e+01$
$1.00e-04$	$7.55e+00$	$2.90e+00$	$9.14e-01$	$1.04e+00$	$1.69e+00$	$1.01e+00$
$1.00e-05$	$7.55e-01$	$2.90e-01$	$9.14e-02$	$1.04e-01$	$1.69e-01$	$1.01e-01$
$1.00e-06$	$7.55e-02$	$2.90e-02$	$9.14e-03$	$1.04e-02$	$1.69e-02$	$1.01e-02$
$1.00e-07$	$7.55e-03$	$2.90e-03$	$9.14e-04$	$1.04e-03$	$1.69e-03$	$1.01e-03$
$1.00e-08$	$7.55e-04$	$2.90e-04$	$9.14e-05$	$1.04e-04$	$1.69e-04$	$1.01e-04$
$1.00e-09$	$7.55e-05$	$2.90e-05$	$9.14e-06$	$1.04e-05$	$1.69e-05$	$1.01e-05$
$1.00e-10$	$7.55e-06$	$2.90e-06$	$9.14e-07$	$1.04e-06$	$1.69e-06$	$1.01e-06$
$1.00e-11$	$7.56e-07$	$2.91e-07$	$9.11e-08$	$1.05e-07$	$1.68e-07$	$1.01e-07$

Fig 12. Numerical convergence of novel mobility scheme on map plots. The figure presents a grid of maps, each illustrating the spatial distribution of normed difference as provided in Table 5 for the respective county. The counties displayed are Cologne, Leverkusen, Rheinisch-Bergischer Kreis, Rhein-Sieg-Kreis, and Bonn. The maps use a logarithmically scaled colorbar. Using geodata "Verwaltungsgebiete 1:2 500 000, Stand 01.01. (VG2500)" from https://gdz.bkg.bund.de, copyright; GeoBasis-DE / BKG 2021, license dl-de/by-2–0, see https://www.govdata.de/dl-de/by-2-0.

Fictional outbreak scenario

In this section, we want to show the impact of the mobility on the evolution of the disease using a fictional outbreak scenario. Therefore, we assume that in the initial stage to only have a single county which has a high amount of exposed people. In this context, we assume 5 % of Cologne's population to be exposed to the virus. Although this number is immense, it was chosen by intention to directly visualize the qualitative propagation of new cases to connected counties.

To emphasize the influence of mobility, we compared our results with the mobility scheme presented in [29] (here denoted *existing instantaneous travel method*, both times using our multi-layer waning immunity model. The advantage of the novel mobility approach accounting for travel and transmission during commuting, contrasting the immediate transfer of travelers in [29].

In the maps of Fig. 13, we illustrate the progression of the total number of currently infected individuals using both approaches over 90 days (excluding Cologne to restrict the colorbar). In particular in the left-most part of the figure, we see that the virus attains counties which have not or almost not been affected with the existing instantaneous travelmethod. We see that the novel approach is leading to a different propagation pattern also easily attaining indirect or loosely coupled regions. The very large number of exposed in Cologne leads to the rapid increase in the upper right part. The second and higher peak in October is due to the waning against any transmission and our seasonality factor in the transmission processes. If we look at the number of infections in all counties except Cologne, a comparison of the median values of the two methods shows that far more individuals will get infected using the novel approach. This is in accordance with the exponential increase in case number in so far virus-free regions. Similar process had been observed for the beginning of the pandemic when only a small number of regions was affected at all. The corresponding process is also reflected in the plots of the maps, where we already see a much more divided infection pattern on the first day.

Fig 13. Propagation of infections with existing instantaneous travel method [29] and novel travel time aware method for an outbreak scenario. Median propagation of infections in German counties (except Cologne) over 90 days with the existing method (top row maps) and the novel method (bottom row maps). In the plots of the right hand side, we provide the evolution of case numbers in Cologne and the rest of Germany. The shaded area visualizes the p25 and p75 percentile results of the 500 ensemble runs. The median value is given as solid line. Using geodata "Verwaltungsgebiete 1:2 500 000, Stand 01.01. (VG2500)" from https://gdz.bkg.bund.de, copyright; GeoBasis-DE / BKG 2021, license dl-de/by-2–0, see https://www.govdata.de/dl-de/by-2-0.

Developments of Post-Oktoberfest until winter season 2022 in Bavaria

To further validate the effect of the novel mobility model, we simulate the Post-Munich Oktoberfest period until the beginning of the winter season 2022. The Oktoberfest, which took place from September 17 to October 3, 2022 and attracted around 5.7 million visitors [69]. Unfortunately, conducted tests have decreased significantly over 2022 and positive rate has been high, see [70] and Fig. 14, which makes reported case numbers quite unreliable and comparisons difficult. On an aggregated level we thus also include reported ICU numbers from [71]. We initialize the model based on the official reported data one week after the festival, at October 10 2022, and simulate until the end of the year using the parameters in Table 3. We adjusted the transmission probability ρ with a factor of 0.8. While the simulate mild cases largely exceed the reported cases (see Fig. 14 (left)), which is no surprise given the low number of tests and high positive rate, the simulated ICU admissions come close to the reported ICU admissions; see Fig. 14 (right).

To provide spatial details of our simulations, we present the simulated number of symptomatic infections in a spatially resolved plot of Bavaria. In Fig. 15, we see the spread of infections across the federal state, with the numbers presented relative to the local population.

Fig 14. Comparison of simulated and reported data for Bavaria and conducted tests. The top left figure shows simulated daily new symptomatic against reported cases in Bavaria, with data smoothed using a 7-day moving average to reduce oscillations. The top right figure compares simulated ICU admissions to reported ICU data. The bottom figure presents the total number of tests conducted alongside with the positive test rate in Bavaria for the entire year 2022.

(a) October 31, 2022   **(b)** November 15, 2022   **(c)** December 1st, 2022

0.001   0.005

Fig 15. Spatial distribution of simulated symptomatic infections in Bavaria for selected days of the Post-Oktoberfest and beginning winter season 2022. Presented values are provided relative to local population.

Late-phase pandemic in Germany   559

We now consider the late-phase SARS-CoV-2 pandemic in Germany. We begin our   560
simulation on August 1st, 2022 and examine the official face mask obligation in public   561
transport, which was maintained until February 2023 and allowed both FFP2 and   562
surgical masks [72]. Beginning October 1, 2022, nationwide enforcement of the use of   563
FFP2 masks on long-distance public transportation [72] was implemented. However,   564
there were differences in local public transportation between the German federal states.   565
In Lower Saxony [73] and Hamburg [74] the FFP2 mask obligations also existed in local   566
public transport but were dropped at the start of October 2022.   567

The newly introduced mobility scheme offers us a flexible approach to implement   568
actions within the mobility node, without necessitating changes to the underlying local   569
model. Within our model, compliance with the mask mandate can be represented by   570
altering the effective contact rate through a damping of the contacts. As shown in [75],   571
the proper usage of FFP2 masks is crucial. For both individuals correctly wearing FFP2   572
masks, the risk of infection during a 20-minute encounter with an infected person was   573
estimated to be as small as 0.1 %. Notably, [75] also demonstrates that without any   574
form of mask-wearing, the probability of infection approaches 100 %. Therefore, we   575
implement the effect of FFP2 masks by a reduction factor of 0.1 % to the effective   576
contact.   577

Throughout much of the pandemic, the German national testing strategy was   578
predominantly focused on testing individuals displaying symptoms [76]. Therefore, we   579
assume that the number of confirmed cases corresponds directly to the daily growth of   580
symptomatic individuals if the detection rate stays constant. This is also in line with   581
the overall decreasing accuracy in positive-testing asymptomatic cases with regard to   582
the Omicron variant [77]. As official reporting was suspected to have large   583
underdetection factors, we based our comparisons not only on the official reported case   584
numbers but also on the self-reported cases in the DigiHero [78] study. We extrapolated   585
the reported infections from 33730 participants in autumn 2022 to the total population   586
of Germany. In Fig. 16 (left), we provide the results of two different ensemble runs with   587
500 individual runs each where either no face masks (blue) or FFP2 (green) masks in   588
transportation have been simulated. We visualize shaded areas for the regions between   589
the p25 and p75 percentiles of the 500 runs and solid lines for the median results.   590

Until beginning of October, Fig. 16 (left) shows substantially larger numbers of   591
infected individuals for the scenario without face masks. The quick decline in numbers   592
in this scenario is due to the very large number of infected individuals before and the   593
temporal immunity saturation obtained. We see that face masks in transportation alone   594
cannot prevent peaking of case numbers. However, the overall peak is considerably   595
smaller (around 20 %). Face masks in transportation can thus contribute in ensuring   596
functionality of critical infrastructure and preventing hospital bed shortages. Compared   597
to reported data, we still see a nonnegligible difference. However, we also assume   598
important underdetection, as test-positive rates range between 30 and 50 %; see [79]. In   599
all curves, we similarly see a first stagnation in numbers and decline of infections   600
towards end of the considered time frame.   601

An important advantage of our approach lies in its ability to quantify infections   602
occurring during participation in traffic, achieved through the utilization of the traffic   603
models. This offers a fundamental advantage over conventional structures. The   604
significantly different probabilities of infection due to the implementation of a mask   605
obligation in the transport models are clearly reflected in the daily number of   606
transmissions in the traffic models obtained by our simulation; see Fig. 16 (center). In   607
order to validate the results obtained by our simulation, we compare to ICU occupancy   608
in Germany from [71] which is a more stable and reliable indicator. In Fig. 16 (right),   609
we see that our model is able to capture the reported ICU occupancy for the second   610

(a) Daily symptomatic infections. (Linear-scaled y-axis)

(b) Daily Transmissions in mobility. (Log-scaled y-axis)

(c) Simulated ICU occupancy compared with real data. (Linear-scaled y-axis)

Fig 16. Daily number of symptomatic infections, transmissions and ICU occupancy. The simulations provide results using correctly worn FFP2 masks (green) and no face masks (blue) in the mobility models. The number of daily symptomatic infections (left, blue and green) is compared to data provided by the DigiHero study (red), where the number of participants is extrapolated to the population in Germany and the official reported cases (yellow). Median values are indicated by the solid lines and shaded areas between the dotted lines represent the p25 and p75 percentiles of the particular ensemble runs. In the center plot, we visualize the daily transmission in the mobility models during the course of the simulation on a logarithmic scale. Furthermore, simulated ICU occupancy with different mask usage (right, blue and green) is compared to reported ICU occupancy (right, orange).

Finally, we want to illustrate the spread of the disease on a geographical basis. 612
In Fig. 17, we provide the (median) daily new numbers of symptomatic infected 613
individuals on county level. This clearly emphasizes once again that the masks, as used 614
only in the mobility models, have a significant influence on the spread of infection. The 615
far higher peak in the case where no face masks are worn is clearly recognizable around 616
day 50. Again, due to a temporal immunity saturation, we find a decline from day 70 to 617
day 90 in the nonrestricted scenario while the face mask scenario numbers decline slower. 618

Fig 17. Daily new number of symptomatic infected individuals on county level. This figure illustrates the change in the daily number of symptomatic infected German counties over the course of 90 days beginning with the 1st August 2022. Each subfigure displays a different day with the two different modes (No masks or FFP2 masks). Using geodata "Verwaltungsgebiete 1:2 500 000, Stand 01.01. (VG2500)" from https://gdz.bkg.bund.de, copyright; GeoBasis-DE / BKG 2021, license dl-de/by-2–0, see https://www.govdata.de/dl-de/by-2-0.

Discussion

The results presented in this study are based on a mean-value model, a multitude of assumptions and different parameters. Although based on an extensive literature review and previous findings in [25, 29, 33], there is still uncertainty about many (virus-specific) parameters. Although the distinction into 3-4 different immunity layers through seropositivity studies [80, 81], a division into three different subpopulations is a rough aggregation. Furthermore, our model is not suited for simulation the evolution of virus variants or the competing circulation of different variants. An inherent limitation of almost all mean-field models and most contact surveys is the difficulty to address (potential) transmission through aerosols which cannot (or only to limited extent) be measured in (direct) contacts so that estimated parameters have to address for this limitation. However, mathematical models can help to explore the mechanisms in infectious disease spread and reasonable assumptions are necessary, even for models up to digital twins. We have waived a lot of unrealistic assumptions such as homogeneous mixture in space and in demography. Our model has been resolved for meaningful regions and demography has been taken into account to model different vulnerabilities for different age groups. In order to better assess model performance under changing

parameters, we have included a sensitivity analysis on the parameters used in the waning immunity model in the appendix. The provided quantification for the different parameter effects will guide extending or reducing the model in future works and analyses.

As we stated ourselves, a critical factor in infectious disease modeling is mobility. Since the ground truth for daily mobility is difficult to grasp, again, assumptions have to be used. We have used the output of a state-of-the-art macroscopic mobility model to be used in our simulations. Different mobility patterns clearly lead to different virus distribution patterns. Furthermore, we have focused on daily mobility activities in this study. The seasonal impact of, e.g., vacation times on travel behavior were not taken into account and influences from abroad have not been included here. For the summer vacation time, where travel activities significantly change with travel from hot or to hot spot regions (outside Germany), our model might need enrichment by an import risk model to reliably capture disease dynamics from the outside.

A precise quantification of waning immunity against different courses of the disease given particular immunization histories is still an open research question. To best cope with this problem, we have considered two large and recent review articles from which we derived most reasonable parameters. However, there is still large uncertainty in several positions which we cannot reduce. Qualitatively, our model could correctly predict stagnation, decline and resurges in considered settings. The effect of waning immunity to SARS-CoV-2 over more than 1 or 2 years, the interplay with new variants or vaccinations is still an open research question our model cannot answer yet.

In order to get meaningful predictions for future developments, our model needs to initialized with reasonable values of the population's immunity. As the reporting of vaccinations is not conducted on personal level and as the dark figure of unreported transmission numbers increased with the end of the pandemic, the current status of the population is difficult to obtain. Serological studies may be needed to provide approximated starting values for future predictions. These limitations in data and assumptions should be kept in mind when interpreting the results of this work.

Conclusion

In this paper, we have presented a novel travel-time aware metapopulation model combined with a novel multi-layer waning immunity model based on ordinary differential equations. Both models advance already existing models for infectious disease dynamics by taking into account yet neglected but essential properties for virus propagation.

The travel-time aware metapopulation model advances existing metapopulation or hybrid graph-ODE approaches by considering travel time as well as transmissions during transport. As unconstrained mobility clearly is a driver for infectious disease dynamics, more realistic mobility modeling increases the reliability of model outcomes. The travel-time aware metapopulation model can directly be combined with any kind of ODE-based transmission model and thus enhances global predictions by correctly resolving heterogeneously different spreading dynamics.

The novel multi-layer waning immunity model copes with the problem of heterogeneous and hybrid immunity in a population in mid- or late-phase pandemics as well as in endemic scenarios. The novel model does not only provide three different populations with different protection factors but also two different paces of waning immunity, i.e., against any transmission and against a severe course of the disease – a property that has been observed for SARS-CoV-2. Given reparameterization, it can also be used for other human-to-human transmittable diseases that show similar developments.

With the combination of both models, we could correctly assess developments in the

late phase of the pandemic in Germany in 2022. Although vaccination could already mitigate the number of severe courses of the diseases, large numbers of mild cases can also have a disastrous impact on economy and critical infrastructure. Our model serves as a good basis for future waves SARS-CoV-2 in upcoming autumn or winter seasons and adaptation to other viruses is possible. The suggested mobility model can be of great help when particular interventions in public transportation are envisaged and expected transmissions can be assessed beforehand. As it can be combined with any kind of ODE-based model, it can also be used for other diseases such as Influenza or RSV.

Supporting information

S1 Appendix. SECIRS-type model equations and initialization.

S2 Appendix. Sensitivity Analysis

S3 Appendix. AMELAG data by federal state

Acknowledgments

The authors HZ, RS, AS, and MJK have received funding by the German Federal Ministry for Digital and Transport under grant agreement FKZ19F2211A, RS has received funding by the German Federal Ministry for Digital and Transport under grant agreement FKZ19F2211B. HZ, DK, MMH, and MJK have received funding from the Initiative and Networking Fund of the Helmholtz Association (grant agreement number KA1-Co-08).

Competing interests

The authors declare to not have any competing interests.

Data availability

The code is publicly available on GitHub under https://github.com/SciCompMod/memilio. The total number of produced simulation data sums up to 200 GB and cannot be uploaded easily. Particular data can be shared upon request. The code and the different models are available on different branches. The introduced SECIRS-type model with waning immunity can be found in branch *323-waning-immunity-model*. The novel mobility model is available in branch *385-mobility-scheme-with-transmission-and-traveltimes*. The combination of both branches and the simulations presented in this paper are available on branch *paper-zunker-simulations-2024*.

Author Contributions

Conceptualization: Henrik Zunker, Martin Kühn, David Kerkmann
Data Curation: Henrik Zunker, Martin Kühn, Alain Schengen, Sophie Diexer
Formal Analysis: Henrik Zunker, Martin Kühn, David Kerkmann
Funding Acquisition: Martin Kühn, Michael Meyer-Hermann, Rafael Mikolajczyk

Investigation: Henrik Zunker, Martin Kühn, David Kerkmann, Alain Schengen 723
Methodology: Henrik Zunker, Martin Kühn, David Kerkmann 724
Project Administration: Martin Kühn 725
Resources: Martin Kühn, Michael Meyer-Hermann, Rafael Mikolajczyk 726
Software: Henrik Zunker, René Schmieding 727
Supervision: Martin Kühn, Michael Meyer-Hermann 728
Validation: All authors 729
Visualization: Henrik Zunker, Martin Kühn 730
Writing – Original Draft: Henrik Zunker, Martin Kühn 731
Writing – Review & Editing: All authors 732

References

1. World Health Organization Team Data, Analytics & Delivery. World health statistics 2023: monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization; 2023. Available from: https://www.who.int/publications/i/item/9789240074323.

2. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. The Lancet. 2022;399(10327):814–823. doi:10.1016/S0140-6736(22)00089-7.

3. Marcelin JR, Pettifor A, Janes H, Brown ER, Kublin JG, Stephenson KE. COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases. 2022;9(5):ofac124. doi:10.1093/ofid/ofac124.

4. Tagesschau. Diese Corona-Regeln gelten ab Oktober; 2022. Available from: https://www.tagesschau.de/inland/innenpolitik/corona-infektionsschutzgesetz-115.html.

5. Berndt JO, Conrad T, Hasenauer J, Karch A, Kheifetz Y, Kirsten H, et al. Szenarien für den Verlauf der SARS-CoV-2-Pandemie im Winter 2022/23 - Ergebnisse eines Workshops des Modellierungsnetzes für schwere Infektionskrankheiten (Modellierungsnetz). Zenodo; 2022. Available from: https://zenodo.org/record/7126032.

6. Memon S, Jadebeck JF, Osthege M, Wendler A, Kerkmann D, Zunker H, et al. Automated Processing of Pipelines Managing Now- and Forecasting of Infectious Diseases. In: 2024 47th MIPRO ICT and Electronics Convention (MIPRO). Opatija, Croatia: IEEE; 2024. p. 1157–1162. Available from: https://ieeexplore.ieee.org/document/10569336/.

7. Betz PK, Stoll J, Grappendorf V, Gilg J, Zeumer M, Klitz M, et al. ESID: Exploring the Design and Development of a Visual Analytics Tool for Epidemiological Emergencies. In: 2023 IEEE VIS Workshop on Visualization for Pandemic and Emergency Responses (Vis4PandEmRes). Melbourne, Australia: IEEE; 2023. p. 8–14. Available from: https://ieeexplore.ieee.org/document/10343886/.

8. Müller SA, Balmer M, Charlton W, Ewert R, Neumann A, Rakow C, et al. Predicting the effects of COVID-19 related interventions in urban settings by combining activity-based modelling, agent-based simulation, and mobile phone data. PLOS ONE. 2021;16(10):e0259037. doi:10.1371/journal.pone.0259037.

9. Tapp L, Kurchyna V, Nogatz F, Berndt JO, Timm IJ. School's out? Simulating schooling strategies during COVID-19. In: International Workshop on Multi-Agent Systems and Agent-Based Simulation. Springer; 2022. p. 95–106.

10. Willem L, Abrams S, Libin PJK, Coletti P, Kuylen E, Petrof O, et al. The impact of contact tracing and household bubbles on deconfinement strategies for COVID-19. Nature Communications. 2021;12(1). doi:10.1038/s41467-021-21747-7.

11. Kerr CC, Stuart RM, Mistry D, Abeysuriya RG, Rosenfeld K, Hart GR, et al. Covasim: An agent-based model of COVID-19 dynamics and interventions. PLOS Computational Biology. 2021;17(7):1–32. doi:10.1371/journal.pcbi.1009149.

12. Bauer S, Contreras S, Dehning J, Linden M, Iftekhar E, Mohr SB, et al. Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves. PLOS Computational Biology. 2021;17(9):e1009288. doi:10.1371/journal.pcbi.1009288.

13. Schüler L, Calabrese JM, Attinger S. Data driven high resolution modeling and spatial analyses of the COVID-19 pandemic in Germany. PLOS ONE. 2021;16(8):e0254660. doi:10.1371/journal.pone.0254660.

14. Rodiah I, Vanella P, Kuhlmann A, Jaeger VK, Harries M, Krause G, et al. Age-specific contribution of contacts to transmission of SARS-CoV-2 in Germany. European Journal of Epidemiology. 2023;38(1):39–58. doi:10.1007/s10654-022-00938-6.

15. Mohring J, Burger M, Feßler R, Fiedler J, Leithäuser N, Schneider J, et al.. Starker Effekt von Schnelltests (Strong effect of rapid tests); 2023. Available from: http://arxiv.org/abs/2304.05938.

16. Wendler AC, Plötzke L, Tritzschak H, Kühn MJ. A nonstandard numerical scheme for a novel SECIR integro differential equation-based model with nonexponentially distributed stay times. 2024;.

17. Kheifetz Y, Kirsten H, Scholz M. On the Parametrization of Epidemiologic Models—Lessons from Modelling COVID-19 Epidemic. Viruses. 2022;14(7):1468. doi:10.3390/v14071468.

18. MacDonald N. Time lags in biological models. vol. 27 of Lecture Notes in Biomathematics. Berlin Heidelberg New York: Springer Science & Business Media; 1978.

19. Contento L, Castelletti N, Raimúndez E, Le Gleut R, Schälte Y, Stapor P, et al. Integrative modelling of reported case numbers and seroprevalence reveals time-dependent test efficiency and infectious contacts. Epidemics. 2023;43:100681. doi:https://doi.org/10.1016/j.epidem.2023.100681.

20. Bicker J, Schmieding R, Meyer-Hermann M, Kühn MJ. Hybrid metapopulation agent-based epidemiological models for efficient insight on the individual scale: a contribution to green computing. 2024;doi:10.48550/arXiv.2406.04386.

21. Pei S, Kandula S, Shaman J. Differential effects of intervention timing on COVID-19 spread in the United States. Science Advances. 2020;6(49):eabd6370. doi:10.1126/sciadv.abd6370.

22. Chen X, Zhang A, Wang H, Gallaher A, Zhu X. Compliance and containment in social distancing: mathematical modeling of COVID-19 across townships. International Journal of Geographical Information Science. 2021;35(3):446–465. doi:10.1080/13658816.2021.1873999.

23. Levin MW, Shang M, Stern R. Effects of short-term travel on COVID-19 spread: A novel SEIR model and case study in Minnesota. PLOS ONE. 2021;16(1):e0245919. doi:10.1371/journal.pone.0245919.

24. Liu J, Ong GP, Pang VJ. Modelling effectiveness of COVID-19 pandemic control policies using an Area-based SEIR model with consideration of infection during interzonal travel. Transportation Research Part A: Policy and Practice. 2022;161:25–47. doi:10.1016/j.tra.2022.05.003.

25. Koslow W, Kühn MJ, Binder S, Klitz M, Abele D, Basermann A, et al. Appropriate relaxation of non-pharmaceutical interventions minimizes the risk of a resurgence in SARS-CoV-2 infections in spite of the Delta variant. PLOS Computational Biology. 2022;18(5):e1010054. doi:10.1371/journal.pcbi.1010054.

26. Bershteyn A, Gerardin J, Bridenbecker D, Lorton CW, Bloedow J, Baker RS, et al. Implementation and applications of EMOD, an individual-based multi-disease modeling platform. Pathogens and Disease. 2018;76(5). doi:10.1093/femspd/fty059.

27. Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College; 2020. Available from: https://www.gov.uk/government/publications/impact-of-non-pharmaceutical-interventions-npis-to-reduce-covid-19-\mortality-and-healthcare-demand-16-march-2020.

28. Brauer F, Castillo-Chavez C, Feng Z. Mathematical models in epidemiology. vol. 32. Springer; 2019.

29. Kühn MJ, Abele D, Mitra T, Koslow W, Abedi M, Rack K, et al. Assessment of effective mitigation and prediction of the spread of SARS-CoV-2 in Germany using demographic information and spatial resolution. Mathematical Biosciences. 2021; p. 108648. doi:https://doi.org/10.1016/j.mbs.2021.108648.

30. Müller SA, Paltra S, Rehmann J, Nagel K, Conrad TOF. Explicit modeling of antibody levels for infectious disease simulations in the context of SARS-CoV-2. iScience. 2023;26(9):107554. doi:10.1016/j.isci.2023.107554.

31. Winkler C, Mocanu T. Methodology and application of a German national passenger transport model for future transport scenarios. In: Proceedings of the 45th European Transport Conference; 2017.

32. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLOS Medicine. 2008;5(3):e74. doi:10.1371/journal.pmed.0050074.

33. Kühn MJ, Abele D, Binder S, Rack K, Klitz M, Kleinert J, et al. Regional opening strategies with commuter testing and containment of new SARS-CoV-2 variants in Germany. BMC Infectious Diseases. 2022;22(1):333. doi:10.1186/s12879-022-07302-9.

34. Marinov TT, Marinova RS. Adaptive SIR model with vaccination: simultaneous identification of rates and functions illustrated with COVID-19. Scientific Reports. 2022;12(1). doi:10.1038/s41598-022-20276-7.

35. Peng R. Asymptotic profiles of the positive steady state for an SIS epidemic reaction–diffusion model. Part I. Journal of Differential Equations. 2009;247(4):1096–1119. doi:https://doi.org/10.1016/j.jde.2009.05.002.

36. Cash JR, Karp AH. A variable order Runge-Kutta method for initial value problems with rapidly varying right-hand sides. ACM Transactions on Mathematical Software. 1990;16(3):201–222. doi:10.1145/79505.79507.

37. Patel MM, York IA, Monto AS, Thompson MG, Fry AM. Immune-mediated attenuation of influenza illness after infection: opportunities and challenges. The Lancet Microbe. 2021;2(12):e715–e725. doi:10.1016/s2666-5247(21)00180-4.

38. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases. 2023;doi:https://doi.org/10.1016/S1473-3099(22)00801-5.

39. Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. The Lancet. 2023;401(10379):833–842. doi:10.1016/s0140-6736(22)02465-5.

40. Kühn MJ, Abele D, Kerkmann D, Korf SA, Zunker H, Wendler AC, et al.. MEmilio v1.0.0 - A high performance Modular EpideMIcs simuLatIOn software; 2023. Available from: https://elib.dlr.de/201660/.

41. Burch E, Khan SA, Stone J, Asgharzadeh A, Dawe J, Ward Z, et al. Early mathematical models of COVID-19 vaccination in high-income countries: a systematic review. Public Health. 2024;236:207–215. doi:10.1016/j.puhe.2024.07.029.

42. Morris MD. Factorial Sampling Plans for Preliminary Computational Experiments. Technometrics. 1991;33(2):161–174. doi:10.1080/00401706.1991.10484804.

43. Winkler C, Mocanu T. Impact of political measures on passenger and freight transport demand in Germany. Transportation Research Part D: Transport and Environment. 2020;87:102476. doi:10.1016/j.trd.2020.102476.

44. Nobis C, Kuhnimhof T. Mobilität in Deutschland – MiD: Ergebnisbericht; 2018. Available from: https://www.mobilitaet-in-deutschland.de/archive/pdf/MiD2017_Ergebnisbericht.pdf.

45. Mocanu T, Joshi J. Generating a microscopic dataset of passenger mobility from a national macroscopic travel demand model and a household travel survey. In: European Transport Conference 2022; 2022.Available from: https://elib.dlr.de/188443/.

46. Kühn M, Schengen A, Mocanu T, Joshi J. Vorläufige bundesweite Verkehrsströme; 2023. Available from: https://mobilithek.info/offers/573360269906817024.

47. Prem K, Cook AR, Jit M. Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLOS Computational Biology. 2017;13(9):e1005697. doi:10.1371/journal.pcbi.1005697.

48. Fumanelli L, Ajelli M, Manfredi P, Vespignani A, Merler S. Inferring the Structure of Social Contacts from Demographic Data in the Analysis of Infectious Diseases Spread. PLoS Computational Biology. 2012;8(9):e1002673. doi:10.1371/journal.pcbi.1002673.

49. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLoS Medicine. 2008;5(3):e74. doi:10.1371/journal.pmed.0050074.

50. Tomori DV, Rübsamen N, Berger T, Scholz S, Walde J, Wittenberg I, et al. Individual social contact data and population mobility data as early markers of SARS-CoV-2 transmission dynamics during the first wave in Germany—an analysis based on the COVIMOD study. BMC Medicine. 2021;19(1). doi:10.1186/s12916-021-02139-6.

51. Klamser PP, Zachariae A, Maier BF, Baranov O, Jongen C, Schlosser F, et al. Inferring country-specific import risk of diseases from the world air transportation network. PLOS Computational Biology. 2024;20(1):e1011775. doi:10.1371/journal.pcbi.1011775.

52. Águila-Mejía JD, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrazo T, Aginagalde-Llorente A. Secondary Attack Rate, Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron Variant, Spain. Emerging Infectious Diseases. 2022;28(6):1224–1228. doi:10.3201/eid2806.220158.

53. Manica M, Bellis AD, Guzzetta G, Mancuso P, Vicentini M, Venturelli F, et al. Intrinsic generation time of the SARS-CoV-2 Omicron variant: An observational study of household transmission. The Lancet Regional Health - Europe. 2022;19:100446. doi:10.1016/j.lanepe.2022.100446.

54. Khalili M, Karamouzian M, Nasiri N, Javadi S, Mirzazadeh A, Sharifi H. Epidemiological characteristics of COVID-19: a systematic review and meta-analysis. Epidemiology and Infection. 2020;148. doi:10.1017/s0950268820001430.

55. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. The Lancet. 2022;399(10335):1618–1624. doi:https://doi.org/10.1016/S0140-6736(22)00327-0.

56. Tobin RJ, Wood JG, Jayasundara D, Sara G, Walker CR, Martin GE, et al. Real-time analysis of hospital length of stay in a mixed SARS-CoV-2 Omicron and Delta epidemic in New South Wales, Australia. BMC Infectious Diseases. 2023;23(1):28. doi:10.1186/s12879-022-07971-6.

57. Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. The Lancet. 2023;401(10379):833–842. doi:https://doi.org/10.1016/S0140-6736(22)02465-5.

58. Wang B, Andraweera P, Elliott S, Mohammed H, Lassi Z, Twigger A, et al. Asymptomatic SARS-CoV-2 Infection by Age: A Global Systematic Review and Meta-analysis. Pediatric Infectious Disease Journal. 2022;42(3):232–239. doi:10.1097/inf.0000000000003791.

59. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet. 2022;399(10332):1303–1312. doi:10.1016/s0140-6736(22)00462-7.

60. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious Diseases. 2020;20(6):669–677. doi:10.1016/S1473-3099(20)30243-7.

61. Relan P, Motaze NV, Kothari K, Askie L, Le Polain de Waroux O, Van Kerkhove MD, et al. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis. BMJ Global Health. 2023;8(7):e012328. doi:10.1136/bmjgh-2023-012328.

62. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia. 2020;75(10):1340–1349. doi:10.1111/anae.15201.

63. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. The Lancet Respiratory Medicine. 2020;8(9):853–862. doi:10.1016/s2213-2600(20)30316-7.

64. Ronchini C, Gandini S, Pasqualato S, Mazzarella L, Facciotti F, Mapelli M, et al. Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs. PLOS ONE. 2022;17(1):e0263014. doi:10.1371/journal.pone.0263014.

65. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine. 2022;386(16):1532–1546. doi:10.1056/nejmoa2119451.

66. UK Health Security Agency. COVID-19 Vaccine Surveillance Report; 2022. Online. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf.

67. Robert Koch-Institut. SARS-CoV-2 Infektionen in Deutschland; 2023. Zenodo. Available from: https://doi.org/10.5281/zenodo.7814948.

68. Robert Koch-Institut F. Abwassersurveillance AMELAG; 2024. Available from: https://doi.org/10.5281/zenodo.13683260.

69. Statista. Anzahl der Besucher auf dem Oktoberfest von 1980 bis 2023; 2024. Available from: https://de.statista.com/statistik/daten/studie/165511/umfrage/anzahl-der-besucher-auf-dem-oktoberfest-seit-1980/.

70. Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit. Anzahl der Laboruntersuchungen auf SARS-CoV-2 in Bayern (Tabelle 11); 2023. Available from: `https://www.lgl.bayern.de/gesundheit/infektionsschutz/infektionskrankheiten_a_z/coronavirus/karte_coronavirus/archiv2.htm`.

71. Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI). DIVI Intensivregister Tagesreport; 2022. Available from: `https://www.divi.de/divi-intensivregister-tagesreport-archiv`.

72. Bundesregierung. Keine Maskenpflicht mehr im Fernverkehr; 2023. Available from: `https://www.bundesregierung.de/breg-de/themen/coronavirus/maskenpflicht-entfaellt-2157682`.

73. Verkehrsverbund Rhein-Berg. Im ÖPNV gilt weiterhin die Maskenpflicht; 2022. Available from: `https://www.vrb-online.de/de/ueber-uns/news/im-%C3%B6pnv-gilt-weiterhin-die-maskenpflicht-296`.

74. NDR. Maskenpflicht in Bussen und Bahnen: Kleine Änderung in Hamburg; 2022. Available from: `https://www.ndr.de/nachrichten/hamburg/coronavirus/Hamburg-Kleine-Aenderung-der-Maskenpflicht-in-Bussen-und-Bahnen,corona11074.html`.

75. Bagheri G, Thiede B, Hejazi B, Schlenczek O, Bodenschatz E. An upper bound on one-to-one exposure to infectious human respiratory particles. Proceedings of the National Academy of Sciences. 2021;118(49). doi:10.1073/pnas.2110117118.

76. Bundesgesundheitsministerium. Fragen und Antworten zu COVID-19 Tests;. `https://www.bundesgesundheitsministerium.de/coronavirus/nationale-teststrategie/faq-covid-19-tests#c25573`.

77. Wagenhäuser I, Knies K, Hofmann D, Rauschenberger V, Eisenmann M, Reusch J, et al. Virus variant–specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022. Clinical Microbiology and Infection. 2023;29(2):225–232. doi:10.1016/j.cmi.2022.08.006.

78. Klee B, Diexer S, Sarajan MH, Glaser N, Binder M, Frese T, et al. Regional Differences in Uptake of Vaccination against COVID-19 and Influenza in Germany: Results from the DigiHero Cohort. Vaccines. 2023;11(11). doi:10.3390/vaccines11111640.

79. Robert Koch-Institut. SARS-CoV-2-PCR-Testungen in Deutschland; 2023. Available from: `https://doi.org/10.5281/zenodo.8069452`.

80. Lange B, Jäger V, Rücker V, Hassenstein M, Harries M, Berner R, et al.. Interimsanalyse des IMMUNEBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an die Modellierungskonsortien der BMBF-geförderten Modellierungsplattform; 2022. Available from: `https://doi.org/10.5281/zenodo.6968574`.

81. Lange B, Jaeger VK, Harries M, Rücker V, Streeck H, Blaschke S, et al. Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project. Infection. 2024;52(1):139–153. doi:10.1007/s15010-023-02071-2.

82. Digitales Impfquotenmonitoring zur COVID-19-Impfung; 2023. Available from:
https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Daten/
Impfquoten-Tab.html.

83. Lange B, Jäger VK, Rücker V, Harries M, Hassenstein MJ, Dreier M, et al.. 2.
Interimsanalyse des IMMUNEBRIDGE-Projektes zur Kommunikation von
vorläufigen Ergebnissen an das Modellierungsnetz für schwere
Infektionskrankheiten; 2022. Available from:
https://doi.org/10.5281/zenodo.7177592.

S1.Appendix: Full waning model equations and initialization

Local SECIRS-type model with waning immunity

In order to present the complete model equations, we define the most important parameters again. For more details, we refer to the subsection *A multi-layer waning immunity model of SECIRS-type.*

For the sake of simplicity, we drop the spatial-dependency superindex $*^{(k)}$. Let $\mu_{z_{j,i}}^{z_{j+1,i}}$ be the probability of transition from disease compartment $z_{j,i}$ to the worsened state $z_{j+1,i}$. Then, $1 - \mu_{z_{j,i}}^{z_{j+1,i}}$ is the probability to recover from disease state $z_{j,i}$. Let further $T_{z_{j,i}}$ be the time in days an individual stays in a compartment $z_{j,i}$. Additionally, we define $N_i^{D^\perp}$ as people from age group i which are not in the dead compartment.

Therefore, the systems of equations is given by

$$\frac{dS_{N,i}}{dt} = -S_{N,i}\rho_{N,i} \sum_{j=1}^{n} \phi_{i,j}$$

$$\frac{\xi_{I_{NS},j}(I_{NS,N,j} + I_{NS,PI,j} + I_{NS,II,j}) + \xi_{I_{Sy},j}(I_{Sy,N,j} + I_{Sy,PI,j} + I_{Sy,II,j})}{N_j^{D^\perp}}$$

$$- v_{N,i}S_{N,i} + \frac{1}{T_{W_{PI}}}S_{PI,i}, \tag{18}$$

$$\frac{dE_{N,i}}{dt} = S_{N,i}\rho_{N,i} \sum_{j=1}^{n} \phi_{i,j}$$

$$\frac{\xi_{I_{NS},j}(I_{NS,N,j} + I_{NS,PI,j} + I_{NS,II,j}) + \xi_{I_{Sy},j}(I_{Sy,N,j} + I_{Sy,PI,j} + I_{Sy,II,j})}{N_j^{D^\perp}}$$

$$- \frac{E_{N,i}}{T_{E_i}}, \tag{19}$$

$$\frac{dI_{NS,N,i}}{dt} = \frac{E_{N,i}}{T_{E_i}} - \frac{I_{NS,N,i}}{T_{I_{NS,i}}}, \tag{20}$$

$$\frac{dI_{NS,N,C,i}}{dt} = -\frac{I_{NS,N,C,i}}{T_{I_{NS,i}}}, \tag{21}$$

$$\frac{dI_{Sy,N,i}}{dt} = \frac{\mu_{I_{NS,N,i}}^{I_{Sy,N,i}}}{T_{I_{NS,i}}}I_{NS,N,i} - \frac{I_{Sy,N,i}}{T_{I_{Sy,i}}}, \tag{22}$$

$$\frac{dI_{Sy,N,C,i}}{dt} = \frac{\mu_{I_{NS,N,i}}^{I_{Sy,N,i}}}{T_{I_{NS,i}}}I_{NS,N,C,i} - \frac{I_{Sy,N,C,i}}{T_{I_{Sy,i}}}, \tag{23}$$

$$\frac{dI_{Sev,N,i}}{dt} = \frac{\mu_{I_{Sy,N,i}}^{I_{Sev,N,i}}}{T_{I_{Sy,i}}}\left(I_{Sy,N,i} + I_{Sy,N,C,i}\right) - \frac{I_{Sev,N,i}}{T_{I_{Sev,i}}}, \tag{24}$$

$$\frac{dI_{Cr,N,i}}{dt} = \frac{\mu_{I_{Sev,N,i}}^{I_{Cr,N,i}}}{T_{I_{Sev,i}}}I_{Sev,N,i} - \frac{I_{Cr,N,i}}{T_{I_{Cr,i}}}, \tag{25}$$

$$\frac{dD_{N,i}}{dt} = \frac{\mu_{I_{Cr,N,i}}^{D_{N,i}}}{T_{I_{Cr,i}}}I_{Cr,N,i}, \tag{26}$$

$$\frac{dS_{PI,i}}{dt} = -S_{PI,i}\rho_{PI,i} \sum_{j=1}^{n} \phi_{i,j}$$

$$\frac{\xi_{I_{NS,j}}(I_{NS,N,j} + I_{NS,PI,j} + I_{NS,II,j}) + \xi_{I_{Sy,j}}(I_{Sy,N,j} + I_{Sy,PI,j} + I_{Sy,II,j})}{N_j^{D^\perp}}$$

$$- v_{PI,i}S_{PI,i} + \frac{1}{T_{\mathcal{T}_{PI,i}}}\mathcal{T}_{PI,i} - \frac{1}{T_{W_{PI}}}S_{PI,i} + \frac{1}{T_{W_{II}}}S_{II,i}, \tag{27}$$

$$\frac{dE_{PI,i}}{dt} = S_{PI,i}\rho_{PI,i}\sum_{j=1}^{n}\phi_{i,j}$$

$$\frac{\xi_{I_{NS,j}}(I_{NS,N,j} + I_{NS,PI,j} + I_{NS,II,j}) + \xi_{I_{Sy,j}}(I_{Sy,N,j} + I_{Sy,PI,j} + I_{Sy,II,j})}{N_j^{D^\perp}}$$

$$- \frac{E_{PI,i}}{T_{E_i}}, \tag{28}$$

$$\frac{dI_{NS,PI,i}}{dt} = \frac{E_{PI,i}}{T_{E_i}} - \frac{I_{NS,PI,i}}{\kappa T_{I_{NS,i}}}, \tag{29}$$

$$\frac{dI_{NS,PI,C,i}}{dt} = -\frac{I_{NS,PI,C,i}}{\kappa T_{I_{NS,i}}}, \tag{30}$$

$$\frac{dI_{Sy,PI,i}}{dt} = \frac{\mu_{I_{NS,PI,i}}^{I_{Sy,PI,i}}}{\kappa T_{I_{NS,i}}}I_{NS,PI,i} - \frac{I_{Sy,PI,i}}{\kappa T_{I_{Sy,i}}}, \tag{31}$$

$$\frac{dI_{Sy,PI,C,i}}{dt} = \frac{\mu_{I_{NS,PI,i}}^{I_{Sy,PI,i}}}{\kappa T_{I_{NS,i}}}I_{NS,PI,C,i} - \frac{I_{Sy,PI,C,i}}{\kappa T_{I_{Sy,i}}}, \tag{32}$$

$$\frac{dI_{Sev,PI,i}}{dt} = \frac{\mu_{I_{Sy,PI,i}}^{I_{Sev,PI,i}}}{\kappa T_{I_{Sy,i}}}\left(I_{Sy,PI,i} + I_{Sy,PI,C,i}\right) - \frac{I_{Sev,PI,i}}{T_{I_{Sev,i}}}, \tag{33}$$

$$\frac{dI_{Cr,PI,i}}{dt} = \frac{\mu_{I_{Sev,PI,i}}^{I_{Cr,PI,i}}}{T_{I_{Sev,i}}}I_{Sev,PI,i} - \frac{I_{Cr,PI,i}}{T_{I_{Cr,i}}}, \tag{34}$$

$$\frac{dD_{PI,i}}{dt} = \frac{\mu_{I_{Cr,PI,i}}^{D_{PI,i}}}{T_{I_{Cr,i}}}I_{Cr,PI,i}, \tag{35}$$

$$\frac{dS_{II,i}}{dt} = -S_{II,i}\rho_{II,i}\sum_{j=1}^{n}\phi_{i,j}$$

$$\frac{\xi_{I_{NS,j}}(I_{NS,N,j} + I_{NS,PI,j} + I_{NS,II,j}) + \xi_{I_{Sy,j}}(I_{Sy,N,j} + I_{Sy,PI,j} + I_{Sy,II,j})}{N_j^{D^\perp}}$$

$$- v_{II,i}S_{II,i} - \frac{1}{T_{W_{II}}}S_{II,i}, \tag{36}$$

$$\frac{dE_{II,i}}{dt} = S_{II,i}\rho_{II,i}\sum_{j=1}^{n}\phi_{i,j}$$

$$\frac{\xi_{I_{NS,j}}(I_{NS,N,j} + I_{NS,PI,j} + I_{NS,II,j}) + \xi_{I_{Sy,j}}(I_{Sy,N,j} + I_{Sy,PI,j} + I_{Sy,II,j})}{N_j^{D^\perp}}$$

$$- \frac{E_{II,i}}{T_{E_i}}, \tag{37}$$

$$\frac{dI_{NS,II,i}}{dt} = \frac{E_{II,i}}{T_{E_i}} - \frac{I_{NS,II,i}}{\kappa T_{I_{NS,i}}}, \tag{38}$$

$$\frac{dI_{NS,II,C,i}}{dt} = -\frac{I_{NS,II,C,i}}{\kappa T_{I_{NS,i}}}, \tag{39}$$

$$\frac{dI_{Sy,II,i}}{dt} = \frac{\mu^{I_{Sy,II,i}}_{I_{NS,II,i}}}{\kappa T_{I_{NS,i}}} I_{NS,II,i} - \frac{I_{Sy,II,i}}{\kappa T_{I_{Sy,i}}}, \tag{40}$$

$$\frac{dI_{Sy,II,C,i}}{dt} = \frac{\mu^{I_{Sy,II,i}}_{I_{NS,II,i}}}{\kappa T_{I_{NS,i}}} I_{NS,II,C,i} - \frac{I_{Sy,II,C,i}}{\kappa T_{I_{Sy,i}}}, \tag{41}$$

$$\frac{dI_{Sev,II,i}}{dt} = \frac{\mu^{I_{Sev,II,i}}_{I_{Sy,II,i}}}{\kappa T_{I_{Sy,i}}} \left(I_{Sy,II,i} + I_{Sy,II,C,i} \right) - \frac{I_{Sev,II,i}}{T_{I_{Sev,i}}}, \tag{42}$$

$$\frac{dI_{Cr,II,i}}{dt} = \frac{\mu^{I_{Cr,II,i}}_{I_{Sev,II,i}}}{T_{I_{Sev,i}}} I_{Sev,II,i} - \frac{I_{Cr,II,i}}{T_{I_{Cr,i}}}, \tag{43}$$

$$\frac{dD_{II,i}}{dt} = \frac{\mu^{D_{II,i}}_{I_{Cr,II,i}}}{T_{I_{Cr,i}}} I_{Cr,II,i}, \tag{44}$$

$$\begin{aligned}
\frac{d\mathcal{T}_{PI,i}}{dt} = &-\frac{1}{T_{\mathcal{T}_{PI,i}}} \mathcal{T}_{PI,i} + \frac{\mu^{\mathcal{T}_{PI,i}}_{I_{NS,N,i}}}{T_{I_{NS,i}}} (I_{NS,N,i} + I_{NS,N,C,i}) \\
&+ \frac{1 - \mu^{I_{Sev,N,i}}_{I_{Sy,N,i}}}{T_{I_{Sy,i}}} (I_{Sy,N,i} + I_{Sy,N,C,i}) \\
&+ \frac{1 - \mu^{I_{Cr,N,i}}_{I_{Sev,N,i}}}{T_{I_{Sev,i}}} I_{Sev,N,i} + \frac{1 - \mu^{D_{N,i}}_{I_{Cr,N,i}}}{T_{I_{Cr,i}}} I_{Cr,N,i} + v_{N,i} S_{N,i},
\end{aligned} \tag{45}$$

$$\begin{aligned}
\frac{d\mathcal{T}_{II,i}}{dt} = &-\frac{1}{T_{\mathcal{T}_{II,i}}} \mathcal{T}_{II,i} + \frac{1 - \mu^{I_{Sy,II,i}}_{I_{NS,PI,i}}}{\kappa T_{I_{NS,i}}} (I_{NS,PI,i} + I_{NS,PI,C,i}) \\
&+ \frac{1 - \mu^{I_{Sev,PI,i}}_{I_{Sy,PI,i}}}{\kappa T_{I_{Sy,i}}} (I_{Sy,PI,i} + I_{Sy,PI,C,i}) \\
&+ \frac{1 - \mu^{I_{Cr,PI,i}}_{I_{Sev,PI,i}}}{T_{I_{Sev,i}}} I_{Sev,PI,i} + \frac{1 - \mu^{D_{PI,i}}_{I_{Cr,PI,i}}}{T_{I_{Cr,i}}} I_{Cr,PI,i} \\
&+ \frac{1 - \mu^{I_{Sy,II,i}}_{I_{NS,II,i}}}{\kappa T_{I_{NS,i}}} (I_{NS,II,i} + I_{NS,II,C,i}) + \frac{1 - \mu^{I_{Sev,II,i}}_{I_{Sy,II,i}}}{\kappa T_{I_{Sy,i}}} (I_{Sy,II,i} + I_{Sy,II,C,i}) \\
&+ \frac{1 - \mu^{I_{Cr,II,i}}_{I_{Sev,II,i}}}{T_{I_{Sev,i}}} I_{Sev,II,i} + \frac{1 - \mu^{D_{II,i}}_{I_{Cr,II,i}}}{T_{I_{Cr,i}}} I_{Cr,II,i} + v_{PI,i} S_{PI,i} + v_{II,i} S_{II,i}.
\end{aligned} \tag{46}$$

An explanation of all used parameters for defining the model in Equations (18) - (46) is provided in Table 6.

Initialization of the introduced compartmental models.

For simplicity, we explain our approach for one age group. It naturally transfers to all other age groups. To determine the initial states for the individual compartments of our model, we use the German case numbers published by the Robert Koch-Institute [67]. Note that any other reporting on the considered geography could be used. In our use case, we perform the initialization on county level. The following descriptions is however possible for any granularity, assuming that the data is available at this level. The initial idea for our approach to use the reported case data as initial states for each compartment was given in [25]. We state that the use of time spans or rates depending on the start **and** target compartment, e.g., T_C^I and T_C^R may have the unwanted effect that μ_C^R no longer represents a probability, as initially assumed and modeled. We thus

Table 6. Parameters used to define our multi-layer waning immunity model of SECIRS-type; Eq (18) - (46).

Parameter	Description
$\phi_{i,j}$	Daily contact rate between two age groups i and j.
$\rho_{0,N}$	Baseline transmission risk for people located in the naive susceptible compartments
k	Seasonality parameter
$N_i^{D^\perp}$	People from age group i which have not died during simulation.
$\mu_{z_1}^{z_2}$	Probability of transition from compartment z_1 to z_2.
T_{z_1}	Time in days an individual stays in a compartment z_1.
$\xi_{I_{NS},i}$	Proportion of asymptomatic infectious people who are not isolated.
$\xi_{I_{Sy},i}$	Proportion of symptomatic infectious people who are not isolated.
κ	Reduction factor for time spans of asymptomatic and symptomatic infections of individuals with partial or improved immunity.
$p_{E_{PI}}$	Effectiveness of partial immunity protection against infection.
$p_{I_{Sy},PI}$	Effectiveness of partial immunity protection against symptomatic infection.
$p_{I_{Sev},PI}$	Effectiveness of partial immunity protection against hospitalization.
$p_{I_{Cr},PI}$	Effectiveness of partial immunity protection against ICU treatment.
$p_{D_{PI}}$	Effectiveness of partial immunity protection against death.
$p_{E_{II}}$	Effectiveness of improved immunity protection against infection.
$p_{I_{Sy},II}$	Effectiveness of improved immunity protection against symptomatic infection.
$p_{I_{Sev},II}$	Effectiveness of improved immunity protection against hospitalization.
$p_{I_{Cr},II}$	Effectiveness of improved immunity protection against ICU treatment.
$p_{D_{II}}$	Effectiveness of improved immunity protection against death.
$T_{W_{PI}}$	Rate of waning immunity of susceptible who are located in the partial immunity state.
$T_{W_{II}}$	Rate of waning immunity of susceptible who are located in the improved immunity state.
v_N	Vaccination rate of people with naive immunity.
v_{PI}	Vaccination rate of susceptible with partial immunity.
v_{II}	Vaccination rate of people with improved immunity.

reduce the description to using $T_C = T_C^I = T_C^R$ and present this approach with additional adjustments to our model.

The idea behind the procedure is to extrapolate the reported numbers of cases only from the model stay times and transition probabilities. We refer to the number of cases (in the particular age group) as $\sum^C(t)$. Similarly, the number of deaths reported (in the particular age group) will be denoted $\sum^D(t)$. Furthermore, we use the accumulated number of partial, full and booster vaccinations (in the particular age group) up to day t [82]. We assign the three different types of vaccination to our immunity layers by referring them to as $\sum^{V_{Y_N}}(t)$ (partial vaccinations), $\sum^{V_{Y_{PI}}}(t)$ (full vaccinations) and $\sum^{V_{Y_{II}}}(t)$ (booster vaccinations).

Following [25], we make the assumption that the number of confirmed cases is proportional to the number of symptomatic cases. Assuming a nontrivial but constant underdetection factor for the initialization phase, we define a factor θ accounting for the

estimated dark figure. The estimated number of reported and unreported symptomatic infections on day t is then given by

$$\widehat{\Sigma}^C(t) = \theta \Sigma^C(t). \tag{47}$$

Furthermore, for simplicity, we assume that detection (or, more general, inclusion into $\widehat{\Sigma}^C(t)$) happens at the time of developing systems. In a generalized approach, an additional shift $\widehat{\Sigma}^C(t + \delta_T)$, with $\delta_T > 0$ a testing or reporting delay, could be added.

As already mentioned in the introduction of the model, we divide the population into three different immunity levels. In [83], an age-resolved breakdown of the German population into four different immunity levels is given. In this study exposure to the virus is defined as a survived infection or vaccination with a corresponding immune response. The classification in four groups is based on the degree of exposure: people with no confirmed exposures, people with one or two confirmed exposures, people with exactly three confirmed exposures and those surpassing three confirmed exposures. Since the proportion of individuals with zero confirmed exposures to date is extremely small, we aggregate them with the group of one or two exposures. Thus, the division takes place into a group N_N with zero, one or two exposures, a group N_{PI} with exactly three exposures, and a group N_{II} with more than three exposures. From the results of [83], we can estimate the immunity of the total population at hand. Next, we explain how we use the reported numbers to estimate the distribution of the population inside the immunity layers.

To determine the initial state of individuals in the exposed state as shown, we proceed as visualized in Fig. 18. Based on our defined transition times, individuals that get exposed at t_0 develop symptoms at $t_0 + T_E + T_{I_{NS}}$ (on average) – and would have been reported or, more generally, included in $\widehat{\Sigma}^C(t_0 + T_E + T_{I_{NS}})$. Individuals who are still exposed at t_0 but become pre- or asymptomatic shortly after that, either develop symptoms by time $t_0 + T_{I_{NS}}$ or will have recovered by then (i.e., will have been included in $\widehat{\Sigma}^C(t_0) + T_{I_{N}S}$). Thus, the total number of exposed at t_0 computes as

$$\sum_{m=1}^{3} E_{Y_m}(t_0) = \left(\frac{1}{\mu_{I_{NS},Y_m}^{I_{Sy},Y_m}} (\widehat{\Sigma}^C(t_0 + T_E + T_{I_{NS}}) - \widehat{\Sigma}^C(t_0 + T_{I_{NS}})) \right). \tag{48}$$

Here, we have added the denominator $\mu_{I_{NS},Y_m}^{I_{Sy},Y_m}$ to account for asymptomatic individuals that recover without ever developing symptoms.

Fig 18. Initialization of the Exposed compartment. For an arbitrary but fixed t_0, individuals who got exposed in the left shaded area (red) will get symptoms or recover in the right shaded area (blue).

We determine the initial number of exposed individuals for any immunity layer Y_m by a uniform distribution to the three immunity layers, i.e.,

$$E_{Y_m}(t_0) = \frac{N_{Y_m}(t_0)}{\sum_{j=1}^{3} N_{Y_j}(t_0)} \left(\frac{1}{\mu_{I_{NS},Y_m}^{I_{Sy},Y_m}} (\widehat{\Sigma}^C(t_0 + T_E + T_{I_{NS}}) - \widehat{\Sigma}^C(t_0 + T_{I_{NS}})) \right). \tag{49}$$

We can adapt this scheme to all other compartments. Therefore, the other equations are

given by

$$I_{NS,Y_m}(t_0) = \frac{N_{Y_m}(t_0)}{\sum_{j=1}^{3} N_{Y_j}(t_0)} \left(\frac{1}{\mu_{I_{NS,Y_m}}^{I_{Sy,Y_m}}} (\widehat{\Sigma}^C(t_0 + T_{I_{NS}}) - \widehat{\Sigma}^C(t_0)) \right),$$

$$I_{Sy,Y_m}(t_0) = \frac{N_{Y_m}(t_0) p_{I_{Sy,Y_m}}}{\sum_{j=1}^{3} N_{Y_j}(t_0) p_{I_{Sy,Y_j}}} \left(\widehat{\Sigma}^C(t_0) - \widehat{\Sigma}^C(t_0 - T_{I_{Sy}}) \right),$$

$$I_{Sev,Y_m}(t_0) = \frac{N_{Y_m}(t_0) p_{I_{Sev,Y_m}}}{\sum_{j=1}^{3} N_{Y_j}(t_0) p_{I_{Sev,Y_j}}} \left(\mu_{I_{Sy,Y_N}}^{I_{Sev,Y_N}} (\widehat{\Sigma}^C(t_0 - T_{I_{Sy}}) - \widehat{\Sigma}^C(t_0 - T_{I_{Sy}} - T_{I_{Sev}})) \right).$$
(50)

Note that for symptomatic and subsequent infection states, we use a nonuniform distribution, taking into account the effectiveness of protection of the different immunity layers against severe courses of the disease. The group $I_{Cr,Y_m}(t_0)$ is intentionally left out here, as it is initialized directly with daily ICU reports from [71].

To calculate the total deaths per immunity layer, it is essential to track the complete historical data on layer sizes and fatalities. In our model, however, we only model the deaths during the simulation phase and initialize

$$D_{Y_m}(t_0) = 0.$$
(51)

Previous death numbers have to be added to the simulation result in post-processing to see the overall number of deaths.

Finally, we need to determine the number of individuals in the temporary immunity and the susceptible compartments at t_0. In order to calculate the number of temporarily immune people, we need to estimate the number of recently recovered $R_{Y_m}^R(t) := \frac{N_{Y_m}(t_0)}{\sum_{j=2}^{3} N_{Y_j}(t_0)} \left(\widehat{\Sigma}^C(t) - \widehat{\Sigma}^C(t - T_{\mathcal{I}_{Y_m}}) \right)$, $Y_m \in \{PI, II\}$ and recently vaccinated $R_{Y_m}^V := \widehat{\Sigma}^{V_{Y_m}}(t) - \widehat{\Sigma}^{V_{Y_m}}(t - T_{\mathcal{I}_{Y_m}})$ individuals within the last $T_{\mathcal{I}_{Y_m}}$ days, $Y_m \in \{PI, II\}$, such that

$$\mathcal{I}_{Y_m}(t) = \min \left\{ N_{Y_m}, \max \left\{ 0, R_{Y_m}^V + R_{Y_m}^R(t) - \sum_m \left(I_{Sy,Y_m}(t) + I_{Sev,Y_m}(t) + I_{Cr,Y_m}(t) \right) \right\} \right\},$$
(52)
(53)

The number of individuals in the susceptible compartment results directly from the remaining population in each layer that has not yet been taken into account in the other compartments.

S2.Appendix

Fig 19. Results of the sensitivity analysis showing the Elementary Effects for the model parameters with respect to the daily new infections (left) and ICU occupancy (right). The impact of each parameter is represented by a logarithmic scaled bar where the length represents the positive and negative influence.

S3.Appendix

Fig 20. Recorded AMELAG wastewater data by federal state – Part 1. Predicted viral load (LOESS regression) per sample location and sorted by federal state as obtained by [68].

Fig 21. Recorded AMELAG wastewater data by federal state – Part 2. Predicted viral load (LOESS regression) per sample location and sorted by federal state as obtained by [68].